Rich Pharmaceuticals (RCHA) S-1 24 Jan 18 2018 Q2 IPO registration Financial data

Document and Entity Information

Document and Entity Information - USD ($)	6 Months Ended
	Sep. 30, 2017	Dec. 29, 2017	Sep. 30, 2016
Document And Entity Information
Entity Registrant Name	Rich Pharmaceuticals, Inc.
Entity Central Index Key	1,504,389
Document Type	S1
Document Period End Date	Sep. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 527,878
Entity Common Stock, Shares Outstanding		955,027,821
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,018

Balance Sheets

Balance Sheets - USD ($)	Sep. 30, 2017	Mar. 31, 2017
Current Assets
Cash and equivalents	$ 24,974	$ 40,903
Notes receivable	15,300	10,000
Total Current Assets	40,274	50,903
Property and equipment, net	1,538	2,125
Securities available for sale	15,000
TOTAL ASSETS	56,812	53,028
Current Liabilities
Accounts payable	312,134	296,635
Accounts payable related party	286,700	53,000
Accrued expenses	1,188,520	937,783
Due to related parties	54,001	49,395
Note payable	920,000	920,000
Convertible notes payable, net of debt discount of $174,572 and $356,819	688,984	514,075
Derivative liabilities	1,912,905	2,607,959
Total Current Liabilities	5,363,244	5,378,847
Long-term Liabilities
Convertible notes payable, net of debt discount
Derivative liabilities
Total Long-term Liabilities
Total Liabilities	5,363,244	5,378,847
Commitments and Contingencies
Stockholders Deficit
Preferred stock, $.001 par value, 10,000,000 shares authorized, 6,000,000 shares issued and outstanding, respectively	6,000	6,000
Common stock, $0.001 par value, 2,000,000,000 shares authorized, 880,678,573 and 101,446,215 shares issued and outstanding,	880,678	101,446
Common stock to be issued	100,000
Additional paid-in capital	6,657,296	7,011,504
Accumulated deficit	(12,950,406)	(12,444,769)
Total Stockholders Deficit	(5,306,432)	(5,325,819)
TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT	$ 56,812	$ 53,028

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2017	Mar. 31, 2017
Statement of Financial Position [Abstract]
Common Stock, Par Value	$ .001	$ 0.001
Common Stock, Shares Authorized	2,000,000,000	2,000,000,000
Common Stock, Issued	880,678,573	101,446,215
Preferred Stock, Par Value	$ .001	$ .001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Issued	6,000,000	6,000,000
Convertible notes payable, debt discount	$ 174,572	$ 356,819

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
REVENUES	$ 115,000		$ 115,000
OPERATING EXPENSES
Consulting expenses	95,375	5,850	100,000	16,075
Office expenses	31,828	35,472	98,231	70,046
Depreciation expense	313	431	586	863
Wages and taxes	139,963	96,001	277,752	191,956
Professional fees	39,942	34,158	104,699	88,401
Regulatory fees	4,182	2,686	38,491	9,529
Research and development	833		148,406
Stock-based compensation
Travel, meals and entertainment	19,027	8,197	34,773	21,403
TOTAL OPERATING EXPENSES	331,463	182,795	802,938	398,272
LOSS FROM OPERATIONS	(216,463)	(182,795)	(687,938)	(398,272)
OTHER INCOME (EXPENSE)
Amortization of debt discount	(330,681)	(25,786)	(681,011)	(72,360)
Change in value of derivative liability	2,465,455	51,683	1,068,465	168,454
Derivative expense			(249,457)
Interest expense	(121,909)	(109,466)	(168,682)	(142,475)
Interest expense related party	(155)	(155)	(308)	(230)
Gain (Loss) on extinguishment of debt			213,294
TOTAL OTHER INCOME EXPENSES	2,012,710	(83,724)	182,301	(46,611)
INCOME/(LOSS) BEFORE PROVISION FOR INCOME TAXES	1,796,247	(266,519)	(505,637)	(444,883)
PROVISION FOR INCOME TAXES
NET INCOME/(LOSS)	$ 1,796,247	$ (266,519)	$ (505,637)	$ (444,883)
NET INCOME/(LOSS) PER SHARE: BASIC AND DILUTED	$ 0	$ 0	$ 0	$ 0
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED	602,711,661	23,050,307	397,523,663	19,935,954

Statements of Operations 12M

Statements of Operations 12M - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Statement [Abstract]
REVENUES
OPERATING EXPENSES
Consulting expenses	45,554	16,000
Office expenses	123,619	110,600
Depreciation expense	1,606	799
Wages and taxes	362,626	383,937
Professional fees	220,411	267,778
Regulatory fees	19,018	29,356
Research and development	71,930	16,823
Stock-based compensation	48,016	240,999
Travel, meals and entertainment	59,037	51,313
TOTAL OPERATING EXPENSES	951,817	1,117,605
LOSS FROM OPERATIONS	(951,817)	(1,118)
OTHER INCOME (EXPENSE)
Amortization of debt discount	(272,184)	(531,638)
Change in value of derivative liability	(1,112,538)	563,432
Derivative expense	(608,949)	(497,213)
Interest expense	(224,828)	(185,136)
Interest expense related party	(536)	(300)
Loss on extinguishment of debt	(70,477)
Other Income Total	(2,289,512)	(650,855)
LOSS BEFORE PROVISION FOR INCOME TAXES	(3,241,329)	(1,768,460)
PROVISION FOR INCOME TAXES
NET LOSS	$ (3,241,329)	$ (1,768,460)
NET LOSS PER SHARE: BASIC AND DILUTED	$ (0.08)	$ (0.47)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED	41,403,529	3,801,064

Statement of Stockholders Equit

Statement of Stockholders Equity (Deficit) - USD ($)	Preferred Stock	Common Stock	Additional Paid-In Capital	Deficit Accumulated	Total
Beginning balance, shares at Mar. 31, 2015	6,000,000	10,818,213
Beginning balance, amount at Mar. 31, 2015	$ 6,000	$ 10,818	$ 6,794,920	$ (9,203,440)	$ (2,391,702)
Stock issued for services, amount			48,016		48,016
Issuance of common stock for cash, shares		317,519
Issuance of common stock for cash, amount		$ 317	48,838		49,155
Warrants issued for services, amount			45,466		45,466
Stock issued for debt conversion, shares		90,628,002
Stock issued for debt conversion, amount		$ 90,628	60,314		150,942
Derivative liability closed to APIC			62,788		62,788
Stock option modification			56,779		56,779
Net loss				(3,274,663)	(1,768,460)
Ending balance, shares at Mar. 31, 2016	6,000,000	10,818,213
Ending balance, amount at Mar. 31, 2016	$ 6,000	$ 10,818	6,794,920	(9,203,440)	(2,391,702)
Stock issued for services, amount			48,016		48,016
Warrants issued for services, amount			45,466		45,466
Stock issued for debt conversion, shares		90,628,002
Stock issued for debt conversion, amount		$ 90,628	60,314		150,942
Derivative liability closed to APIC			62,788		62,788
Net loss				(3,241,329)	(3,241,329)
Ending balance, shares at Mar. 31, 2017	6,000,000	101,446,215
Ending balance, amount at Mar. 31, 2017	$ 6,000	$ 101,446	$ 7,011,504	$ (12,444,769)	(5,325,819)
Net loss					(505,637)
Ending balance, amount at Sep. 30, 2017					$ (5,306,432)

Statements of Cash Flows

Statements of Cash Flows - USD ($)	6 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period	$ (505,637)	$ (444,883)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense	586	863
Amortization of debt discount	681,011	72,360
Change in value of derivative liability	(1,068,465)	(168,454)
Derivative expense	249,457
Gain on extinguishment of debt	(213,294)
Warrants issued for services
Stock-based compensation
Changes in operating assets and liabilities:
Decrease in prepaid expenses		2,800
Increase (decrease) in bank overdraft		(800)
Increase in accounts payable	249,199	111,299
Increase in accrued expenses	313,250	236,377
Net Cash Used by Operating Activities	(293,893)	(190,438)
CASH FLOWS FROM INVESTING ACTIVITY:
Increase in notes receivable	(5,300)
Increase in stock held for investment	(15,000)
Net Cash Used by Investing Activities	(20,300)
CASH FLOWS FROM FINANCING ACTIVITIES:
Loans received (repaid) from/to related parties	4,606	(37,812)
Proceeds from sale of common stock and warrants	100,000
Proceeds from issuance of note payable
Proceeds from issuance of convertible notes payable	193,658	228,250
Net Cash Provided by Financing Activities	298,264	190,438
Net Increase (Decrease) in Cash and Cash Equivalents	(15,929)
Cash and cash equivalents, beginning of period	40,903
Cash and cash equivalents, end of period	24,974
SUPPLEMENTAL CASH FLOW INFORMATION:
Interest paid
Income taxes paid
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING INFORMATION:
Accounts payable converted into note payable		900,000
Warrants issued for accrued expenses
Original issue discounts recorded on notes payable	10,000
Debt discounts recorded on convertible notes payable	498,764
Debt/interest converted into common stock and contributed capital	$ 277,208	$ 70,478

Statements of Cash Flows 12M

Statements of Cash Flows 12M - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period	$ (3,241,329)	$ (1,768,460)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense	1,606	799
Amortization of debt discount	272,184	531,638
Change in value of derivative liability	1,112,538	(563,432)
Derivative expense	608,949	497,213
Loss on extinguishment of debt	70,477
Interest converted into stock	11,010
Warrants issued for services	45,466
Stock-based compensation	48,016	240,999
Changes in operating assets and liabilities:
Decrease in prepaid expenses	2,800	4,778
Increase (decrease) in bank overdraft	(2,948)	2,948
Increase in accounts payable	110,204	229,159
Increase in accrued expenses	407,633	329,259
Net Cash Used by Operating Activities	(553,394)	(495,099)
CASH FLOWS FROM INVESTING ACTIVITY:
Increase in notes receivable	(10,000)
Acquisition of assets		(3,741)
Net Cash Used by Investing Activities	(10,000)	(3,741)
CASH FLOWS FROM FINANCING ACTIVITIES:
Loans received (repaid) from/to related parties	(27,518)	70,846
Proceeds from sale of common stock and warrants		49,155
Proceeds from issuance of note payable	20,000
Proceeds from issuance of convertible notes payable	611,815	362,947
Net Cash Provided by Financing Activities	604,297	482,948
Net Increase (Decrease) in Cash and Cash Equivalents	40,903	(15,892)
Cash and cash equivalents, beginning of period		15,892
Cash and cash equivalents, end of period	40,903
SUPPLEMENTAL CASH FLOW INFORMATION:
Interest paid
Income taxes paid
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING INFORMATION:
Accounts payable converted into note payable	900,000
Warrants issued for accrued expenses	36,000
Original issue discounts recorded on notes payable	30,000	12,900
Debt discounts recorded on convertible notes payable	543,858	498,544
Debt/interest converted into common stock and contributed capital	$ 389,100	$ 602,374

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended	12 Months Ended
	Sep. 30, 2017	Mar. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Nature of Business On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”). On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 41,384 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000. On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 265,646 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 250,128 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 131,261 common shares. (All shares stated at post-split amounts.) On September 5, 2013, the Company increased the authorized common shares, par value $0.0010, from 900,000 shares to 375,030,000 shares. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. Effective June 7, 2017, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 20 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At September 30, 2017 and March 31, 2017 the Company had $24,974 and $40,903, respectively, of unrestricted cash. Basis of Presentation The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end. Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2017, as filed with the U.S. Securities and Exchange Commission. Property and Equipment Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years. Long-Lived and Intangible Assets The Company accounts for long-lived and intangible assets in accordance with ASC Topic 360-10-05, “Accounting for the Impairment or Disposal of Long-Lived Assets.” ASC Topic 360-10-05 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the historical cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the carrying value of an asset by estimating the future net cash flows expected to result from the asset, including eventual disposition. If the future net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset’s carrying value and fair value or disposable value. Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value: Level 1 – Observable inputs such as quoted prices in active markets; Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company did not have any level 3 financial instruments at September 30, 2017 or March 31, 2017. As of September 30, 2017, the securities available for sale were considered a level 1 item (see note 3); the derivative liabilities were considered a level 2 item (see Note 9). Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The Company has made all adjustments necessary for a fair presentation of the interim financial information and all such adjustments are normal and recurring in nature, as required under ASC Topic 270. Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. Revenue Recognition The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured. Research and Development The Company will charge research and development costs to expense when incurred. The research and development costs include payments made to unrelated third party vendors for their work on enhancements to existing technology, or research into new potentially patentable products or processes. Stock-Based Compensation Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 195,002 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 9,875 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 195,000 stock options to officers, directors, employees and consultants. During the period ended March 31, 2017, the Company granted 29,000,000 stock options to officers, directors, employees and consultants. The Company made the following modifications to the exercise prices of its options: January 12, 2015, the Company modified the exercise price on all outstanding stock options to $3.40; April 6, 2015, the Company modified the exercise price on all outstanding stock options to $1.60 per share; August 4, 2015, the Company modified the exercise price on all outstanding stock options to $0.20 per share. (All shares are stated at post-split amounts). Basic Loss Per Share The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. Total potentially dilutive instruments are: 9,446,533 common share warrants, and 29,195,000 common shares upon exercise of outstanding options. In periods of net losses the dilutive loss per share is the same as the basic loss per share because the effect of the dilutive shares in periods of loss is antidilutive. Recent Accounting Pronouncements The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.	Nature of Business On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”). On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 41,384 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000. On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 265,646 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 250,128 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 131,261 common shares. On September 5, 2013, the Company increased the authorized common shares, par value $0.0010, from 900,000 shares to 375,030,000 shares. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. Effective June 7, 2017, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 20 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At March 31, 2017 and 2016 the Company had $40,903 and $-, respectively, of unrestricted cash. Basis of Presentation The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end. Property and Equipment Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years. Long-Lived and Intangible Assets The Company accounts for long-lived and intangible assets in accordance with ASC Topic 360-10-05, “Accounting for the Impairment or Disposal of Long-Lived Assets.” ASC Topic 360-10-05 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the historical cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the carrying value of an asset by estimating the future net cash flows expected to result from the asset, including eventual disposition. If the future net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset’s carrying value and fair value or disposable value. As of March 31, 2014, the Company fully impaired their intangible assets to $0. During the year ended March 31, 2015, the Company acquired another intangible asset from a related party and valued it at the cost of the intangible to the related party totaling $82,120. As of March 31, 2015, the Company fully impaired their intangible assets to $0. Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value: Level 1 – Observable inputs such as quoted prices in active markets; Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company did not have any level 1 or level 3 financial instruments at March 31, 2017 or March 31, 2016. As of March 31, 2017, the derivative liabilities were considered a level 2 item; see Note 8. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. Revenue Recognition The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured. Research and Development The Company will charge research and development costs to expense when incurred. The research and development costs include payments made to unrelated third party vendors for their work on enhancements to existing technology, or research into new potentially patentable products or processes. Stock-Based Compensation Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 195,002 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 9,875 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 195,000 stock options to officers, directors, employees and consultants. During the period ended March 31, 2017, the Company granted 29,000,000 stock options to officers, directors, employees and consultants. The Company made the following modifications to the exercise prices of its options: January 12, 2015, the Company modified the exercise price on all outstanding stock options to $3.40; April 6, 2015, the Company modified the exercise price on all outstanding stock options to $1.60 per share; August 4, 2015, the Company modified the exercise price on all outstanding stock options to $0.20 per share. Basic Loss Per Share The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. Recent Accounting Pronouncements The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

Property and equipment

Property and equipment	6 Months Ended	12 Months Ended
	Sep. 30, 2017	Mar. 31, 2017
Property, Plant and Equipment [Abstract]
Property and equipment	Property and equipment, recorded at cost, consisted of the following as of September 30, 2017 and March 31, 2017: September 30, 2017 March 31, 2017 Computer equipment & furniture $ 5,160 $ 5,160 Less: accumulated depreciation (3,622 ) (3,035 ) Property and equipment, net $ 1,538 $ 2,125 The useful life of the computer equipment and furniture is 3 years. Depreciation expense was $586 and $1,606 for the periods ended September 30, 2017 and March 31, 2017, respectively.	Property and equipment, recorded at cost, consisted of the following as of March 31, 2017 and 2016: March 31, 2017 March 31, 2016 Computer equipment & furniture $ 5,160 $ 5,160 Less: accumulated depreciation (3,035 ) (1,429 ) Property and equipment, net $ 2,125 $ 3,731 The useful life of the computer equipment and furniture is 3 years. Depreciation expense was $1,606 and $799 for the periods ended March 31, 2017 and 2016, respectively.

Securities Available For Sale

Securities Available For Sale	6 Months Ended
	Sep. 30, 2017
Investments, Debt and Equity Securities [Abstract]
Securities Available For Sale	The Company received 15,000,000 common stock shares of an entity that is majority owned by a non-majority stockholder of the Company designating the two entities as under common control. This transaction is partial payment for access to the Company’s intellectual property. This holding represents about 11% of the ownership of the invested company. The Company classifies its equity securities held as available for sale, and as such, they are carried at fair value. Changes in fair value of available for sale securities will be reported as a component of other comprehensive income and evaluated at the end of each quarter. The shares currently do not have a firm quoted trading price and thus they are carried at their par value until such time as the shares have established a trading price in the market. It should be noted that recording this transaction at par value of the securities is the same treatment recorded by the issuing company due to the lack of active market and lack of transferability of the shares.

Intangible Assets

Intangible Assets	6 Months Ended	12 Months Ended
	Sep. 30, 2017	Mar. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 41,384 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. This asset was made accessible to a related party as part of a support and collaboration agreement dated July 11, 2017, in exchange for payment including 15,000,000 shares of the related parties common stock and cash of $100,000. This agreement does not diminish the Company’s ability to use or benefit from this asset. See note 3. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 110,396 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0. This asset was made accessible to a related party as part of a support and collaboration agreement dated July 11, 2017, in exchange for payment including 15,000,000 shares of the related parties common stock and cash of $100,000. This agreement does not diminish the Company’s ability to use or benefit from this asset. See note 3.	On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 41,384 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 110,396 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0.

Accrued Expenses

Accrued Expenses	6 Months Ended	12 Months Ended
	Sep. 30, 2017	Mar. 31, 2017
Payables and Accruals [Abstract]
Accrued Expenses	Accrued expenses consisted of the following as of September 30, 2017 and March 31, 2017: September 30, 2017 March 31, 2017 Wages and taxes $ 1,012,457 $ 829,231 Accrued interest 176,063 108,552 Total accrued expenses $ 1,188,520 $ 937,783	Accrued expenses consisted of the following as of March 31, 2017 and 2016: March 31, 2017 March 31, 2016 Wages and taxes $ 829,231 $ 514,713 Accrued interest 108,552 15,437 Total accrued expenses $ 937,783 $ 530,150

Related Party Debt and Transact

Related Party Debt and Transactions	6 Months Ended	12 Months Ended
	Sep. 30, 2017	Mar. 31, 2017
Related Party Transactions [Abstract]
Related Party Debt and Transactions	During the year ended March 31, 2015, the Company received a $6,000 loan from a shareholder. During the period ended March 31, 2017 the Company received an additional $6,280 from this related party. The loan is unsecured and bears 8% interest and has an original due date of January 8, 2016. There is a total due of $12,280 as of September 30, 2017 and March 31, 2017. Interest accrued on the note as of September 30, 2017 was $1,211. The Company is in default on the balance of this note. During the period ending March 31, 2016, the Company received $22,200 in unsecured non-interest bearing loans from related parties and during the period ending March 31, 2017 received an additional $14,450, and has repaid $36,300 of these loans leaving a total due of $350 as of September 30, 2017. These loans are deemed to be short-term and are payable at the discretion of the Company. Periodically, related parties incur expenses for the Company and are expected to be repaid for those expenditures. As of September 30, 2017, the balance owed to related parties for these types of expenses is $40,160. These liabilities do not have stated interest rates or due dates, but are payable at the discretion of the Company. The Company has a consulting agreement with a related party to provide research into new technologies as well as essential development of current products. The amounts owed to this related party for past work is a part of accounts payable and totals $286,700 and $53,000 for the periods ending September 30, 2017 and March 31, 2017, respectively. On September 6, 2013, the Company entered into an Employment Agreement with our Chief Executive Officer, Chief Financial Officer, President and Secretary. The Employment Agreement provides for a term of two years, and has been extended through November 2018; annual compensation of $275,000, a signing bonus of $68,750, and options to purchase up to 1,500 shares of common stock at an exercise price of $40.00 per share. The CEO earned $137,500 and $275,000 for the six months ended September 30, 2017 and the twelve months ended March 31, 2017 (respectively) as a result of this agreement, these amounts contribute to the $737,611 and $645,945 of officer compensation which is included in accrued expenses, as of September 30, 2017 and March 31, 2017. The intangible assets (as described in note 4) were made accessible to a related party as part of a support and collaboration agreement dated July 11, 2017, in exchange for payment including 15,000,000 shares of the related parties common stock and cash of $100,000. This agreement accounts for all of the $115,000 of revenue recognized by the Company.	During the year ended March 31, 2015, the Company received a $6,000 loan from a shareholder. During the period ended March 31, 2017 the Company received an additional $6,280 from this related party. The loan is unsecured and bears 8% interest. There is a total due of $12,280 as of March 31, 2017. Interest accrued on the note as of March 31, 2017 and 2016 was $903 and $267, respectively. The Company is in default on the balance of this note. During the period ending March 31, 2016, the Company received $22,200 in unsecured non-interest bearing loans from related parties and during the period ending March 31, 2017 received an additional $14,450, and has repaid $36,300 of these loans leaving a total due of $350 as of March 31, 2017. These loans are deemed to be short-term and are payable at the discretion of the Company. On September 6, 2013, the Company entered into an Employment Agreement with our Chief Executive Officer, Chief Financial Officer, President and Secretary. The Employment Agreement provides for a term of two years, and has been extended for an additional two years; annual compensation of $275,000, a signing bonus of $68,750, and options to purchase up to 1,500 shares of common stock at an exercise price of $40.00 per share. The CEO earned $275,000 and $275,000 for the periods ended March 31, 2017 and 2016 (respectively) as a result of this agreement, these amounts contribute to the $645,945 and $395,630 of officer compensation which is included in accrued expenses, as of March 31, 2017 and 2016.

Note Payable

Note Payable	6 Months Ended	12 Months Ended
	Sep. 30, 2017	Mar. 31, 2017
Debt Disclosure [Abstract]
Note Payable	On May 31, 2016, the Company issued a secured promissory note in the amount of $900,000. The note is due on August 1, 2017 and bears interest at 10% per annum. The loan replaced an account payable to a legal professional to cover past due amounts and penalties for non-payment. The note is guaranteed personally by two shareholders and collateralized by assets of the company and guarantors. Accrued interest was $120,082 as of September 30, 2017. On February 21, 2017, the Company issued a non-secured promissory note in the amount of $20,000. The note is due on August 21, 2017 and bears interest at 8% per annum. The loan was in payment for professional fees related to an equity financing agreement dated February 21, 2017, thus no cash was received by the Company. Accrued interest was $969 as of September 30, 2017.	On May 31, 2016, the Company issued a secured promissory note in the amount of $900,000. The note is due on August 1, 2017 and bears interest at 10% per annum. The loan replaced an account payable to a legal professional to cover past due amounts and penalties for non-payment. The note is guaranteed personally by two shareholders and collateralized by assets of the company and guarantors. Accrued interest was $74,959 as of March 31, 2017. On February 21, 2017, the Company issued a non-secured promissory note in the amount of $20,000. The note is due on August 21, 2017 and bears interest at 8% per annum. The loan was in payment for professional fees related to an equity financing agreement dated February 21, 2017, thus no cash was received by the Company. Accrued interest was $167 as of March 31, 2017.

Convertible Note Payable

Convertible Note Payable	6 Months Ended	12 Months Ended
	Sep. 30, 2017	Mar. 31, 2017
Debt Disclosure [Abstract]
Convertible Note Payable	On February 5, 2015, the Company issued a convertible promissory note in the amount of $54,000. The note is due on November 9, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,020 in principal into 619,652 shares of common stock, and incurred a default fee of $27,000 leaving a remaining balance of $47,980. On February 22, 2017, this note was purchased for a renegotiated face value of $59,799, incurring additional financing fees of $11,819. (details are provided under the note dated February 22, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0. On March 9, 2015, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and was originally due on December 9, 2015, with a revised due date of June 23, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $38,785 in principal and $5,135 in accrued interest into 2,886,693 shares of common stock. During the period ending June 30, 2016 the note holder converted $7,377 in principal and $422 in accrued interest into 2,324,229 shares of common stock leaving a remaining balance of $ 8,838. On March 26, 2015, the Company issued a convertible note payable in the amount of $29,680 including an original issue discount of $1,680. The note bears 8% interest and is due on March 23, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) days prior to the conversion date. During the period ending March 31, 2016 the note holder converted $10,929 in principal into 796,236 shares of common stock leaving a remaining balance of $18,751. The Company is in default on the balance of this note. On May 5, 2015, the Company issued a convertible note payable in the amount of $68,900 including an original issue discount of $3,900. The note bears 8% interest and is due on May 5, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 42% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. . During the period ending March 31, 2016 the note holder converted $8,461 in principal and $566 in accrued interest into 906,763 shares of common stock. During the period ending March 31, 2017 the note holder converted $60,439 in principal and $6,839 in accrued interest into 44,551,004 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of . On May 6, 2015, the Company issued a convertible note payable in the amount of $10,500. The note bears 8% interest and is due on February 8, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the thirty (30) trading day period ending on the latest complete trading day prior to the conversion date. The Company incurred a default fee of $5,250, leaving a balance of $15,750 as of . On August 28, 2015, the Company issued a convertible note payable in the amount of $15,000. The note bears 8% interest and is due on August 28, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending the note holder converted $15,000 in principal and $939 in accrued interest into 4,351,619 shares of common stock leaving a remaining balance of $0. On September 4, 2015, the Company issued a convertible note payable in the amount of $19,000. The note bears 8% interest and is due on June 4, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the fifteen (15) trading day period ending on the latest complete trading day prior to the conversion date. On December 29, 2015, the Company issued a convertible note payable in the amount of $57,378. The note bears 8% interest rate and was originally due on December 30, 2016 , The loan becomes convertible on , 2015, the issue date of the note. The loan can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period prior to the conversion date. During the period ending March 31, 2016 the note holder converted $59,934 in principal and $1,222 in accrued interest into 1,796,394 shares of common stock, and incurred a default penalty of $4,165, leaving a remaining balance of $1,609. On January 22, 2016, the Company issued a convertible note payable in the amount of $60,500. The note bears 10% interest and is due on October 22, 2016. The loan becomes convertible on January 22, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty (20) trading day period prior to the conversion date. On February 25, 2016, the Company issued a convertible note payable in the amount of $27,500. The note bears 8% interest rate and is due on February 25, 2017. The loan becomes convertible on , the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending the note holder converted $16,745 in principal and $1,380 in interest into 3,325,000 shares of common stock leaving a remaining balance of $10,755. On March 24, 2016, the Company issued a convertible note payable in the amount of $7,500. The note bears 8% interest rate and is due on March 24, 2017. The loan becomes convertible on , the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. On May 25, 2016, the Company issued a convertible note payable in the amount of $30,000. The note bears 8% interest and is due on May 25, 2017. The loan becomes convertible 180 days after issuance or November 21, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. On June 8, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $84,250. The note bears interest at the rate of 8% and must be repaid on or before June 8, 2017. The note and any accrued interest may be converted into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. On February 20, 2017, this note was consolidated with other outstanding convertible notes and purchased for a renegotiated face value of $134,214, incurring additional financing fees of $49,964. (details are provided under the note dated February 20, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0. On June 23, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $56,000. The note bears interest at the rate of 8% and must be repaid on or before June 23, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. As of September 30, 2017 the accrued interest balance is $5,695. On July 7, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $58,000. The note bears interest at the rate of 8% and must be repaid on or before July 7, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, On October 20, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $32,000. The note bears interest at the rate of 8% and must be repaid on or before October 20, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, On November 17, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $56,000. The note bears interest at the rate of 8% and must be repaid on or before June 23, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, On January 5, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $335,000. The note bears interest at the rate of 10%, contains a $30,000 OID, and must be repaid by October 5, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or January 5, 2017, On February 20, 2017, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $563,028 which is partially funded, the current balance consolidates unpaid convertible notes dated March 9, 2015; September 4, 2015; December 29, 2015; February 25, 2016; March 24, 2016; May 25, 2016; June 8, 2016; June 23, 2016; July 7, 2016; October 20, 2016; November 17, 2016. The note bears interest at the rate of 8%, and must be repaid by October 25, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 20, 2017, On February 21, 2017, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $15,000. The note bears interest at the rate of 8%, and must be repaid by October 25, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 21, 2017, On February 22, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $59,799, which refinances an unpaid convertible note dated February 5, 2015. The note bears interest at the rate of 10%, and must be repaid by October 25, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 22, 2017, On February 22, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $20,900, which refinances an unpaid convertible note dated May 6, 2015. The note bears interest at the rate of 10%, and must be repaid by October 22, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 22, 2017, On April 4, 2017, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $71,457, which refinances an unpaid convertible note dated January 22, 2016. The note bears interest at the rate of 8%, and must be repaid by January 4, 2018. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or , On April 18, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $115,000. The note bears interest at the rate of 10%, a 10% original issue discount and the lender will hold $5000 to cover transaction costs, the note must be repaid by January 30, 2018. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or ,	On August 13, 2014, the Company issued a convertible note payable in the amount of $61,111 including an original issue discount of $5,500. The note has a one-time 12% interest charge and is due on August 14, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $61,111 of principal and $6,266 of interest into 70,185 shares of common stock leaving a remaining balance of $0. During the year ended March 31, 2016, the note holder converted $1,067 of interest into 8,892 shares of common stock leaving a remaining balance of accrued interest of $0 as of March 31, 2016. On September 18, 2014, the Company issued a convertible note payable in the amount of $64,500 including an original issue discount of $5,500. The note bears a one-time 12% interest charge and is due on September 18, 2015. The loan becomes convertible immediately upon the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. However, if the market price during the 20 day trading period (mentioned above) is below $0.03, then the conversion factor will be reduced to 55%. During the year ended March 31, 2015, the note holder converted $10,000 of principal into 9,091 shares of common stock leaving a remaining balance of $54,500. During the period ending March 31, 2016 the note holder converted $54,500 in principal and $8,240 in accrued interest into 93,980 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On September 23, 2014, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and is due on June 23, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $25,200 of the principle into 35,000 common shares leaving a remaining balance of $29,800. During the period ending March 31, 2016 the note holder converted $29,800 in principal and $2,158 in accrued interest into 43,234 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On October 6, 2014, the Company issued a convertible promissory note in the amount of $33,000. The note is due on July 6, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,000 in principal and $1,320 in accrued interest into 39,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On November 6, 2014, the Company issued a convertible promissory note in the amount of $55,000. The note is due on May 6, 2015 and bears interest at 12% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 52.5% multiplied by lowest daily market price, for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $55,000 in principal and $3,553 in accrued interest into 140,682 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On November 25, 2014, the Company issued a convertible promissory note in the amount of $43,000. The note is due on August 28, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder assessed a default fee of $3,510 to increase the balance of the note and also converted $46,510 in principal into 264,514 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On December 16, 2014, the Company issued a convertible note payable in the amount of $33,333 including an original issue discount of $3,333. The note bears a one-time 12% interest charge and is due on December 16, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,333 in principal and $4000 in accrued interest into 252,358 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On January 9, 2015, the Company issued a convertible promissory note in the amount of $33,000. The note is due on October 13, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder assessed a default fee of $16,500 to increase the balance of the note and also converted $49,500 in principal and $1,320 in interest into 423,500 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On February 5, 2015, the Company issued a convertible promissory note in the amount of $54,000. The note is due on November 9, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,020 in principal into 619,652 shares of common stock, and incurred a default fee of $27,000 leaving a remaining balance of $47,980. On February 22, 2017, this note was purchased for a renegotiated face value of $59,799, including accrued interest of $6,416 and incurring a loss on extinguisment of debt of $5,403. (details are provided under the note dated February 22, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0. On February 17, 2015, the Company issued a convertible note payable in the amount of $66,780 including an original issue discount of $6,780. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $66,780 in principal and $3,148 in accrued interest into 442,702 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On February 25, 2015, the Company issued a convertible note payable in the amount of $27,778 including an original issue discount of $2,778. The note bears a one-time 12% interest charge and is due on February 25, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $27,778 in principal and $3,333 in accrued interest into 259,261 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On March 9, 2015, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and was originally due on December 9, 2015, with a revised due date of June 23, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $38,785 in principal and $5,135 in accrued interest into 2,886,693 shares of common stock. During the period ending June 30, 2016 the note holder converted $7,377 in principal and $422 in accrued interest into 2,324,229 shares of common stock leaving a remaining balance of $ 8,838. On March 26, 2015, the Company issued a convertible note payable in the amount of $29,680 including an original issue discount of $1,680. The note bears 8% interest and is due on March 23, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) days prior to the conversion date. During the period ending March 31, 2016 the note holder converted $10,929 in principal into 796,236 shares of common stock leaving a remaining balance of $18,751. The Company is in default on the balance of this note. On March 2, 2015, the Company issued a convertible note payable in the amount of $58,300 including an original issue discount of $3,300. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible immediately at the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty-two (22) trading day period ending on the latest complete trading day prior to the conversion date. On March 2, 2015 the note holder converted $56,402 of the principle into 60,778 common shares leaving a remaining balance of $1,898. During the period ending March 31, 2016 the note holder converted $1,898 in principal and $20 in accrued interest into 2,650 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On May 5, 2015, the Company issued a convertible note payable in the amount of $68,900 including an original issue discount of $3,900. The note bears 8% interest and is due on May 5, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 42% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. . During the period ending March 31, 2016 the note holder converted $8,461 in principal and $566 in accrued interest into 906,763 shares of common stock. During the period ending March 31, 2017 the note holder converted $60,439 in principal and $6,839 in accrued interest into 44,551,004 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of . On May 6, 2015, the Company issued a convertible note payable in the amount of $10,500. The note bears 8% interest and is due on February 8, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the thirty (30) trading day period ending on the latest complete trading day prior to the conversion date. The Company incurred a default fee of $5,250, leaving a balance of $15,750 as of . On May 27, 2015, the Company issued a convertible note payable in the amount of $16,500. The note bears 8% interest rate and is due on May 28, 2016. The loan becomes convertible on May 27, 2015, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $16,500 in principal and $344 in accrued interest into 129,566 shares of common stock leaving a remaining balance of $0. On August 28, 2015, the Company issued a convertible note payable in the amount of $15,000. The note bears 8% interest and is due on August 28, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending the note holder converted $15,000 in principal and $939 in accrued interest into 4,351,619 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2017. On September 4, 2015, the Company issued a convertible note payable in the amount of $19,000. The note bears 8% interest and is due on June 4, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the fifteen (15) trading day period ending on the latest complete trading day prior to the conversion date. On December 29, 2015, the Company issued a convertible note payable in the amount of $57,378. The note bears 8% interest rate and was originally due on December 30, 2016, with a revised due date of June 23, 2017. The loan becomes convertible on , 2015, the issue date of the note. The loan can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period prior to the conversion date. During the period ending March 31, 2016 the note holder converted $59,934 in principal and $1,222 in accrued interest into 1,796,394 shares of common stock, and incurred a default penalty of $4,165, leaving a remaining balance of $1,609. On January 22, 2016, the Company issued a convertible note payable in the amount of $60,500. The note bears 10% interest and is due on October 22, 2016. The loan becomes convertible on January 22, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty (20) trading day period prior to the conversion date. Interest accrued as of is $7,194. The Company is in default on the balance of this note. On February 25, 2016, the Company issued a convertible note payable in the amount of $27,500. The note bears 8% interest rate and is due on February 25, 2017. The loan becomes convertible on , the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date.. During the period ending the note holder converted $16,745 in principal and $1,380 in interest into 3,325,000 shares of common stock leaving a remaining balance of $10,755. On March 24, 2016, the Company issued a convertible note payable in the amount of $7,500. The note bears 8% interest rate and is due on March 24, 2017. The loan becomes convertible on , the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. On May 25, 2016, the Company issued a convertible note payable in the amount of $30,000. The note bears 8% interest and is due on May 25, 2017. The loan becomes convertible 180 days after issuance or November 21, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. On June 8, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $84,250. The note bears interest at the rate of 8% and must be repaid on or before June 8, 2017. The note and any accrued interest may be converted into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. On February 20, 2017, this note was consolidated with other outstanding convertible notes and purchased for a renegotiated face value of $134,214, including accrued interest of $5,226 and incurring a loss on extinguishment of debt of $44,738. (details are provided under the note dated February 20, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0. On June 23, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $56,000. The note bears interest at the rate of 8% and must be repaid on or before June 23, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. As of March 31, 2017 the accrued interest balance is $3,449. On July 7, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $58,000. The note bears interest at the rate of 8% and must be repaid on or before July 7, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, On October 20, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $32,000. The note bears interest at the rate of 8% and must be repaid on or before October 20, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, On November 17, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $56,000. The note bears interest at the rate of 8% and must be repaid on or before June 23, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, On January 5, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $285,000. The note bears interest at the rate of 10%, contains a $30,000 OID, and must be repaid by October 5, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or January 5, 2017, On February 20, 2017, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $243,313, which consolidated unpaid convertible notes dated March 9, 2015; September 4, 2015; December 29, 2015; February 25, 2016; March 24, 2016; May 25, 2016; June 8, 2016. The note bears interest at the rate of 8%, and must be repaid by October 25, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 20, 2017, leaving a remaining balance of $208,943 On February 21, 2017, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $15,000. The note bears interest at the rate of 8%, and must be repaid by October 25, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 21, 2017, On February 22, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $59,799, which refinances an unpaid convertible note dated February 5, 2015. The note bears interest at the rate of 10%, and must be repaid by October 25, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 22, 2017, On February 22, 2017, the Company issued a 10% Convertibe Redeemable Promissory Note in the principal amount of $20,900, which refinances an unpaid convertible note dated May 6, 2015. The note bears interest at the rate of 10%, and must be repaid by October 22, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 22, 2017,

Derivative Liabilities

Derivative Liabilities	6 Months Ended	12 Months Ended
	Sep. 30, 2017	Mar. 31, 2017
Notes to Financial Statements
Derivative Liabilities	In accordance with AC 815, the Company has bifurcated the conversion feature of their convertible notes and recorded a derivative liability on the date each note became convertible. The derivative liability was then revalued on each reporting date. As detailed in Note 7 (above) the Company has issued several convertible notes in varying amounts and terms, with the following loans becoming convertible during the periods ending September 30, 2017 and March 31, 2017: $29,680 note dated March 26, 2015; $60,500 note dated January 22, 2016 $56,000 note dated June 23, 2016; $58,000 note dated July 7, 2016; $32,000 note dated October 20, 2016; $56,000 note dated November 17, 2016; $335,000 note dated January 5, 2017; $563,028 note dated February 20, 2017; $15,000 note dated February 21, 2017; $59,799 note dated February 22, 2017; $20,900 note dated February 22, 2017; $71,457 note dated April 4, 2017; $115,000 note dated April 18, 2017. ASC 815 requires Company management to assess the fair market value of certain derivatives at each reporting period and recognize any change in the fair market value as another income or expense item. The Company’s only asset or liability measured at fair value on a recurring basis is its derivative liability associated with the above convertible debt. During the period ended September 30, 2017, the Company recorded a total change in the fair market value of the derivative liabilities of $1,068,465. The Company uses the Black-Scholes option pricing model to value the derivative liability upon the initial conversion date and at each reporting period. Included in the model to value the derivative liabilities of the above loans are the following assumptions: stock price at valuation date of $0.0009-$0.004, exercise price of $0.0003 - $0.001, dividend yield of zero, years to maturity of 0.0137 – .5863, a risk free rate of 0.77% - 1.2%, and annualized volatility of 204% - 668%. The above loans were all discounted in full. Based on the valuations on the initial valuation dates for the period ending September 30, 2017, the Company recognized debt discounts related to the conversion features totaling $681,011 and a derivative expense of $249,457 related to the excess value of the derivative liabilities. Once the loans are fully converted, the remaining derivative liability is reclassified to equity as additional paid-in capital. As of September 30, 2017, unamortized debt discount, including original issue discounts totaled $174,572. The derivative liabilities totaled $1,912,905 as of September 30, 2017, of which $- related to long-term debt.	In accordance with AC 815, the Company has bifurcated the conversion feature of their convertible notes and recorded a derivative liability on the date each note became convertible. The derivative liability was then revalued on each reporting date. As detailed in Note 7 (above) the Company has issued several convertible notes in varying amounts and terms, with the following loans becoming convertible during the periods ending March 31, 2017 and March 31, 2016: $33,000 noted dated October 6, 2014; $55,000 note dated November 6, 2014; $43,000 note dated November 25, 2014; $33,000 note dated January 9, 2015; $54,000 note dated February 5, 2015; $66,780 note dated February 17, 2015;$58,300 note dated March 2, 2015; $55,000 note dated March 9, 2015; $29,680 note dated March 26, 2015; $68,900 note dated May 5, 2015; $10,500 note dated May 6, 2015; $16,500 note dated May 27, 2015; $15,000 note dated August 28, 2015; $19,000 note dated September 4, 2015; $55,000 note dated December 29, 2015; $60,500 note dated January 22, 2016; $27,500 note dated February 25, 2016; $7,500 note dated March 24, 2016; $30,000 note dated May 25, 2016; $84,250 note dated June 8, 2016; $56,000 note dated June 23, 2016; $58,000 note dated July 7, 2016; $285,000 note dated January 5, 2017; $243,313 note dated February 20, 2017; $15,000 note dated February 21, 2017; $59,799 note dated February 22, 2017; $20,900 note dated February 22, 2017. ASC 815 requires Company management to assess the fair market value of certain derivatives at each reporting period and recognize any change in the fair market value as another income or expense item. The Company’s only asset or liability measured at fair value on a recurring basis is its derivative liability associated with the above convertible debt. During the period ended March 31, 2017, the Company recorded a total change in the fair market value of the derivative liabilities of $1,112,538. The Company uses the Black-Scholes option pricing model to value the derivative liability upon the initial conversion date and at each reporting period. Included in the model to value the derivative liabilities of the above loans are the following assumptions: stock price at valuation date of $0.0001-$0.0002, exercise price of $0.00005 - $0.0006, dividend yield of zero, years to maturity of 0.060270 – .64660, a risk free rate of 0.53% - 0.91%, and annualized volatility of 0% - 841%. The above loans were all discounted in full with the exception of the March 2, 2015 loan which had a debt discount of $46,370, the May 5, 2015 loan which had an initial debt discount of $41,222, and the May 27, 2015 loan which had an initial debt discount of $15,000. Based on the valuations on the initial valuation dates for the period ending March 31, 2017, the Company recognized debt discounts related to the conversion features totaling $563,858 and a derivative expense of $852,262 related to the excess value of the derivative liabilities. Once the loans are fully converted, the remaining derivative liability is reclassified to equity as additional paid-in capital. As of March 31, 2017, unamortized debt discount, including original issue discounts totaled $356,819. The derivative liabilities totaled $2,607,959 as of March 31, 2017, of which $- related to long-term debt.

Equity Transactions

Equity Transactions	6 Months Ended	12 Months Ended
	Sep. 30, 2017	Mar. 31, 2017
Equity Transactions
Equity Transactions	The Company has 2,000,000,000 common shares authorized with a par value of $ 0.001 per share. The Company has 10,000,000 preferred shares authorized with a par value of $ 0.001 per share. The following is a summary of the inputs used to determine the value of the warrants issued in connection with common stock using the Black-Scholes option pricing model. Date March 30, 2017 Warrants 9,200,000 Stock price on grant date $0.002 Exercise price $0.002 Expected life 5 year Volatility 120% Risk-free rate 1.96% Calculated value $15,278 Fair value allocation of proceeds $45,466 The following is a summary of the warrant activity for the period March 31, 2017 to September 30, 2017: Number of warrants Weighted average exercise price Outstanding, March 31, 2017 9,446,533 $ 0.102 Granted — — Exercised — — Outstanding, September 30, 2017 9,446,533 $ 0.102 Effective June 7, 2017, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 20 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. During the period ended September 30, 2017, the Company issued common stock to satisfy convertible debt conversions at a price below par value as obligated by contract. During this period the Company issued 779,232,358 common shares at a below par rate, incurring an adjustment to additional paid in capital of $502,027. During August 2017, the Company received $100,000 from a related party as consideration for a stock subscription agreement dated October 16, 2017. The agreement stipulates issuance of 333,333,333 common stock and an additional warrants to purchase another 333,333,333 common shares at $0.0003 per share for a five year term. As of September 30, 2017, the Company has not fulfilled this obligation, thus the $100,000 collected on this agreement is recorded as common stock to be issued in the financial statements until shares are issued to complete this transaction. During the period ended March 31, 2017, the Company received, as listed, conversion notices from various note holders. The Company issued the following common shares to satisfy the conversion of the following debt and interest: Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2016 $2,197 488,316 $ 0.00450 April 4, 2016 $4,847 862,500 $ 0.00562 April 7, 2016 $1,750 486,111 $ 0.00360 April 14, 2016 $4,158 962,500 $ 0.00432 April 15, 2016 $1,318 488,311 $ 0.00270 April 26, 2016 $1,705 631,489 $ 0.00270 May 4, 2016 $2,067 485,901 $ 0.00426 May 31, 2016 $ 828 230,003 $ 0.00360 June 2, 2016 $9,120 1,500,000 $ 0.00608 June 2, 2016 $4,401 1,467,017 $ 0.00300 June 14, 2016 $5,847 1,461,795 $ 0.00400 June 17,2016 $5,691 1,422,808 $ 0.00400 June 29, 2016 $6,580 1,063,518 $ 0.00618 August 23, 2016 $2,567 1,106,487 $ 0.00232 August 29, 2016 $2,570 1,107,806 $ 0.00232 September 6, 2016 $2,547 1,097,634 $ 0.00232 September 20, 2016 $2,443 1,263,383 $ 0.00194 September 26, 2016 $2,946 1,269,672 $ 0.00232 September 28, 2016 $2,947 1,270,172 $ 0.00232 September 30, 2016 $3,949 2,553,336 $ 0.00154 October 7, 2016 $3,381 2,914,578 $ 0.00116 October 14, 2016 $3,380 2,913,784 $ 0.00116 October 21, 2016 $3,385 2,917,784 $ 0.00116 October 26, 2016 $3,382 2,915,828 $ 0.00116 October 31, 2016 $5,037 4,341,852 $ 0.00116 November 7 , 2016 $5,015 4,323,647 $ 0.00116 November 22, 2016 $5,513 4,753,008 $ 0.00116 November 29, 2016 $5,515 4,754,647 $ 0.00116 December 6, 2016 $4,058 3,497,965 $ 0.00116 January 10, 2017 $6,301 6,301,150 $ 0.00100 February 22, 2017 $4,290 3,575,000 $ 0.00120 March 13, 2017 $4,080 3,400,000 $ 0.00120 March 21, 2017 $4,920 4,100,000 $ 0.00120 March 22, 2017 $5,160 4,300,000 $ 0.00120 March 24, 2017 $5,460 4,550,000 $ 0.00120 March 30, 2017 $5,645 4,800,000 $ 0.00118 March 31, 2017 $5,939 5,050,000 $ 0.00118 March 31, 2017 Total $150,939 90,628,002 During the period ended September 30, 2017, the Company received, as listed, conversion notices from various note holders. The Company issued the following common shares to satisfy the conversion of the following debt and interest: Date Debt/Interest Converted Common Stock Issued Price per Share April 5, 2017 $6,233 5,300,000 $0.00118 April 10, 2017 $6,586 5,600,000 $0.00118 April 11, 2017 $6,880 5,850,000 $0.00118 April 18, 2017 $7,291 6,200,000 $0.00118 April 20, 2017 $7,644 6,500,000 $0.00118 April 21, 2017 $16,464 14,000,000 $0.00118 April 25, 2017 $17,287 14,700,000 $0.00118 April 26, 2017 $26,600 26,600,000 $0.00100 May 1, 2017 $8,700 14,500,000 $0.00060 June 13, 2017 $1,200 10,000,000 $0.00012 June 16, 2017 $1,930 19,299,400 $0.00010 June 16, 2017 $1,300 11,000,000 $0.00012 June 20, 2017 $1,392 11,600,000 $0.00012 June 21, 2017 $2,314 23,139,900 $0.00010 June 22, 2017 $1,590 13,250,000 $0.00012 June 22, 2017 $1,470 12,250,000 $0.00012 June 26, 2017 $1,800 15,000,000 $0.00012 June 29, 2017 $1,980 16,500,000 $0.00012 July 3, 2017 $2,088 17,400,000 $0.00012 July 12, 2017 $2,088 17,400,000 $0.00012 July 13, 2017 $2,484 13,800,000 $0.00018 July 14, 2017 $3,374 19,000,000 $0.00018 July 18, 2017 $3,374 19,000,000 $0.00018 July 20, 2017 $3,582 19,900,000 $0.00018 July 24, 2017 $6,270 20,900,000 $0.0003 July 25, 2017 $6,870 22,900,000 $0.0003 July 28, 2017 $7,200 24,000,000 $0.0003 August 2, 2017 $7,200 24,000,000 $0.0003 August 4, 2017 $9,000 25,000,000 $0.00036 August 8, 2017 $11,119 26,475,000 $0.00042 August 11, 2017 $13,920 29,000,000 $0.00048 August 16, 2017 $12,810 30,500,000 $0.00042 August 22, 2017 $6,709 19,168,058 $0.00035 August 25, 2017 $11,200 32,000,000 $0.00035 August 31, 2017 $9,600 32,000,000 $0.0003 September 7, 2017 $9,900 36,000,000 $0.00028 September 15, 2017 $9,437 37,900,000 $0.00025 September 22, 2017 $9,910 39,800,000 $0.00025 September 28, 2017 $10,408 41,800,000 $0.00025 September 30, 2017 Total $277,204 779,232,358 (2) Effective April 6, 2015, the Company approved the re-pricing of all 135,627 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $1.60 per share and $3.40 per share, to $1.60 per share which was the closing price of the Company’s common stock on April 6, 2015. All of the other terms of the options remained unchanged. (3) Effective August 4, 2015, the Company approved the re-pricing of all 185.627 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $1.60 per share and $0.40 per share, to $0.40 per share which was the closing price of the Company’s common stock on August 4, 2015. All of the other terms of the options remained unchanged. The Company revalued all existing options on January 12, 2015 and again on April 6, 2015, and again on August 4, 2015 using the Black-Scholes option pricing model using the initial terms of the options and the modified terms of the options. The difference in the valuations was recorded as additional expense. The re-pricing of the options resulted in the recognition of an additional $50,448 on January 9, 2015 and an additional $9,316 on April 6, 2015, and an additional $47,463 on August 4, 2015 in related stock based compensation expense for those periods. The following is a summary of the inputs used to determine the value of the options using the Black-Scholes option pricing model. Date April 6, 2015 June 9, 2015 December 15, 2015 March 30, 2017 Options 102,000 50,000 43,000 29,000,000 Stock price grant date $1.60 $0.40 $0.20 $0.002 Initial Exercise price $1.60 $0.40 $0.20 $0.002 Modified Exercise price $0.20 $0.20 $0.20 - Expected life 5.0 5.0 5.0 5.0 Volatility 99% 99% 84% 120% Risk-free rate 1.31% 1.74% 1.70% 1.93% Calculated value $120,778 $14,838 $5,736 $48,017 Modified value $151,221 $16,347 $5,736 $48,017 The following is a summary of the option activity for the period March 31, 2017 through September 30, 2017: Number of options Weighted average exercise price Outstanding, March 31, 2017 29,228,627 $ 0.004 Granted — — Exercised — — Expired — — Outstanding, September 29,228,627 $ 0.004 The Company accounts for employee stock-based compensation in accordance with the guidance of ASC Topic 718: Compensation - Stock Compensation, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values The Company follows ASC Topic 505-50, formerly EITF 96-18, “Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling Goods and Services,” for stock options and warrants issued to consultants and other non-employees. In accordance with ASC Topic 505-50, these stock options issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option, whichever can be more clearly determined.	The Company has 2,000,000,000 common shares authorized with a par value of $ 0.001 per share. The Company has 10,000,000 preferred shares authorized with a par value of $ 0.001 per share. On July 18, 2013, the Company designated, from the 10,000,000 authorized shares of preferred stock, 6,000,000 shares of Series “A” Preferred Stock. The Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company granted 6,000,000 Series “A” Preferred shares and 41,384 common shares for the intellectual property. The common and preferred shares were valued at a total of $123,973. On July 19, 2013, our new officer/director agreed to cancel 250,128 common shares and returned them to treasury. Certain other shareholders also agreed to cancel 131,261 common shares. On September 5, 2013, the Company increased the authorized common shares from 900,000 to 375,030,000. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. On October 29, 2013, the Company granted 125 units at $600.00 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $1,000.00 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On December 11, 2013, the Company granted 125 units at $600.00 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $1,000.00 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On June 9, 2015, the Company issued 45,000 units at $0.40 per unit. Each unit consisted of one common stock warrant with an exercise price of $0.40 and a five year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On December 15, 2015, the Company issued 200,000 units at $0.20 per unit. Each unit consisted of one common stock warrant with an exercise price of $0.20 and a five year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. The following is a summary of the inputs used to determine the value of the warrants issued in connection with common stock using the Black-Scholes option pricing model. Date June 9, 2015 Dec 15,2015 March 30, 2017 Warrants 45,000 200,000 9,200,000 Stock price on grant date $0.40 $0.20 $0.002 Exercise price $0.40 $0.20 $0.002 Expected life 5 year 5 year 5 year Volatility 98% 98% 120% Risk-free rate 1.74% 1.71% 1.96% Calculated value $13,259 $29,612 $15,278 Fair value allocation of proceeds $13,259 $29,612 $45,466 The following is a summary of the warrant activity for the period March 31, 2016 to March 31, 2017: Number of warrants Weighted average exercise price Outstanding, March 31, 2016 246,533 $3.84 Granted 9,200,000 $0.002 Exercised - - Outstanding, March 31, 2017 9,446,556 $0.102 On April 22, 2015, the Company sold 5,019 shares of common stock for $5,405 in cash, which was paid directly to a vendor for accounts payable. On June 25, 2015, the Company sold 77,123 shares of common stock for $10,797 in cash, of which $3,750 was paid directly to professionals in connection with the expenses of that sale, and $7,047 was retained by the Company. On July 7, 2015, the Company sold 80,971 shares of common stock for $11,336 in cash, of which $3,750 was paid directly to a vendor for professional services. On July 15, 2015, the Company sold 71,964 shares of common stock for $10,075 in cash. On October 27, 2015, the Company sold 82,442 shares of common stock for $11,542 in cash. On February 8, 2016, the Company approved a change in the authorized shares of common stock to 4,000,000,000 shares. Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. On May 9, 2017, the Company approved the reduction of the number of authorized $0.001 par value common stock from 40,000,000,000 common shares to 2,000,000,000 common shares. These financial statements reflect the change in authorized stock. Effective June 7, 2017, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 20 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. During the year ended March 31, 2014, the Company granted 23,752 stock options to officers, directors, employees and consultants. During the year ended March 31, 2015, the Company granted 9,875 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 195,000 stock options to officers, directors, employees and consultants The options have been re-priced twice as follows: (1) Effective January 12, 2015, the Company approved the re-pricing of all 33,627 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $38.40 per share and $600.00 per share, to $3.40 per share which was the closing price of the Company’s common stock on January 9, 2015. All of the other terms of the options remained unchanged. During the periods ended March 31, 2017 and March 31, 2016, the Company received, as listed, conversion notices from various note holders. The Company issued the following common shares to satisfy the conversion of the following debt and interest: Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2015 $16,650 20,556 $0.81000 April 6, 2015 $10,000 10,482 $0.95400 April 8, 2015 $15,309 22,678 $0.67500 April 8, 2015 $20,001 22,727 $0.88000 April 9, 2015 $14,320 16,273 $0.88000 April 14, 2015 $10,000 11,848 $0.84400 April 16, 2015 $1,918 2,650 $0.72380 April 21, 2015 $10,000 12,987 $0.77000 April 29, 2015 $15,000 19,481 $0.77000 May 4, 2015 $5,083 6,573 $0.77320 May 12, 2015 $28,456 45,169 $0.63000 May 20, 2015 $20,199 47,382 $0.42620 May 20, 015 $17,240 39,182 $0.44000 May 27, 2015 $13,568 35,090 $0.38660 May 29, 2015 $15,000 44,118 $0.34000 June 11, 2015 $9,897 47,130 $0.21000 June 16, 2015 $14,100 58,750 $0.24000 June 16, 2015 $13,565 56,521 $0.24000 June 22, 2015 $7,415 61,792 $0.12000 June 22, 2015 $14,384 123,996 $0.11600 June 23, 2015 $7,752 64,600 $0.12000 September 16, 2015 $7,974 88,602 $0.09000 September 28, 2015 $10,000 83,333 $0.12000 September 29, 2015 $10,620 88,500 $0.12000 October 7, 2015 $2,250 18,750 $0.12000 October 7, 2015 $8,400 70,000 $0.12000 October 19, 2015 $9,720 81,000 $0.12000 November 2, 2015 $4,424 98,306 $0.04500 November 23, 2015 $10,000 83,333 $0.12000 November 30, 2015 $16,844 129,566 $0.13000 December 9, 2015 $1,746 38,800 $0.04500 December 17, 2015 $5,332 45,966 $0.11600 December 28, 2015 $1,341 29,810 $0.04500 December 28, 2015 $17,700 147,500 $0.12000 December 28, 2015 $14,305 119,208 $0.12000 December 28, 2015 $14,963 128,996 $0.11600 December 29, 2015 $8,395 69,958 $0.12000 December 29, 2015 $7,670 63,917 $0.12000 December 30, 2015 $6,651 147,812 $0.04500 January 1, 2016 $28,500 219,231 $0.13000 January 4, 2016 $19,339 161,161 $0.12000 January 5, 2016 $8,107 180,161 $0.04500 January 6, 2016 $16,070 133,917 $0.12000 January 6, 2016 $16,597 143,080 $0.11600 February 16 ,2016 $1,424 211,020 $0.00680 February 17, 2016 $12,800 422,164 $0.03040 February 23, 2016 $4,640 210,909 $0.02200 February 23, 2016 $3,086 210,044 $0.01460 February 24, 2016 $1,492 220,999 $0.00680 February 25, 2016 $3,000 131,949 $0.02280 February 25, 2016 $4,640 210,909 $0.02200 March 1, 2016 $1,313 291,723 $0.00440 March 2, 2016 $4,600 291,582 $0.01580 March 2, 2016 $1,650 129,321 $0.01280 March 2, 2016 $9,332 582,500 $0.01600 March 7, 2016 $2,799 327,315 $0.00860 March 11, 2016 $1,924 207,375 $0.00920 March 14, 2016 $2,245 356,289 $0.00640 March 15, 2016 $3,329 372,705 $0.00900 March 15, 2016 $5,210 572,500 $0.00920 March 22, 2016 $2,419 447,894 $0.00540 March 22, 2016 $2,367 360,023 $0.00660 March 22, 2016 $5,315 584,100 $0.00920 March 28, 2016 $1,986 447,939 $0.00440 March 31, 2016 Total $602,376 9,730,152 Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2016 $2,197 488,316 $ 0.00450 April 4, 2016 $4,847 862,500 $ 0.00562 April 7, 2016 $1,750 486,111 $ 0.00360 April 14, 2016 $4,158 962,500 $ 0.00432 April 15, 2016 $1,318 488,311 $ 0.00270 April 26, 2016 $1,705 631,489 $ 0.00270 May 4, 2016 $2,067 485,901 $ 0.00426 May 31, 2016 $ 828 230,003 $ 0.00360 June 2, 2016 $9,120 1,500,000 $ 0.00608 June 2, 2016 $4,401 1,467,017 $ 0.00300 June 14, 2016 $5,847 1,461,795 $ 0.00400 June 17,2016 $5,691 1,422,808 $ 0.00400 June 29, 2016 $6,580 1,063,518 $ 0.00618 August 23, 2016 $2,567 1,106,487 $ 0.00232 August 29, 2016 $2,570 1,107,806 $ 0.00232 September 6, 2016 $2,547 1,097,634 $ 0.00232 September 20, 2016 $2,443 1,263,383 $ 0.00194 September 26, 2016 $2,946 1,269,672 $ 0.00232 September 28, 2016 $2,947 1,270,172 $ 0.00232 September 30, 2016 $3,949 2,553,336 $ 0.00154 October 7, 2016 $3,381 2,914,578 $ 0.00116 October 14, 2016 $3,380 2,913,784 $ 0.00116 October 21, 2016 $3,385 2,917,784 $ 0.00116 October 26, 2016 $3,382 2,915,828 $ 0.00116 October 31, 2016 $5,037 4,341,852 $ 0.00116 November 7 , 2016 $5,015 4,323,647 $ 0.00116 November 22, 2016 $5,513 4,753,008 $ 0.00116 November 29, 2016 $5,515 4,754,647 $ 0.00116 December 6, 2016 $4,058 3,497,965 $ 0.00116 January 10, 2017 $6,301 6,301,150 $ 0.00100 February 22, 2017 $4,290 3,575,000 $ 0.00120 March 13, 2017 $4,080 3,400,000 $ 0.00120 March 21, 2017 $4,920 4,100,000 $ 0.00120 March 22, 2017 $5,160 4,300,000 $ 0.00120 March 24, 2017 $5,460 4,550,000 $ 0.00120 March 30, 2017 $5,645 4,800,000 $ 0.00118 March 31, 2017 $5,939 5,050,000 $ 0.00118 March 31, 2017 Total $150,939 90,628,002 (2) Effective April 6, 2015, the Company approved the re-pricing of all 135,627 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $1.60 per share and $3.40 per share, to $1.60 per share which was the closing price of the Company’s common stock on April 6, 2015. All of the other terms of the options remained unchanged. (3) Effective August 4, 2015, the Company approved the re-pricing of all 185.627 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $1.60 per share and $0.40 per share, to $0.40 per share which was the closing price of the Company’s common stock on August 4, 2015. All of the other terms of the options remained unchanged. The Company revalued all existing options on January 12, 2015 and again on April 6, 2015, and again on August 4, 2015 using the Black-Scholes option pricing model using the initial terms of the options and the modified terms of the options. The difference in the valuations was recorded as additional expense. The re-pricing of the options resulted in the recognition of an additional $50,448 on January 9, 2015 and an additional $9,316 on April 6, 2015, and an additional $47,463 on August 4, 2015 in related stock based compensation expense for those periods. The following is a summary of the inputs used to determine the value of the options using the Black-Scholes option pricing model. Date April 6, 2015 June 9, 2015 December 15, 2015 March 30, 2017 Options 102,000 50,000 43,000 29,000,000 Stock price grant date $1.60 $0.40 $0.20 $0.002 Initial Exercise price $1.60 $0.40 $0.20 $0.002 Modified Exercise price $0.20 $0.20 $0.20 - Expected life 5.0 5.0 5.0 5.0 Volatility 99% 99% 84% 120% Risk-free rate 1.31% 1.74% 1.70% 1.93% Calculated value $120,778 $14,838 $5,736 $48,017 Modified value $151,221 $16,347 $5,736 $48,017 The following is a summary of the option activity for the period March 31, 2016 through March 31, 2017: Number of options Weighted average exercise price Outstanding, March 31, 2016 228,627 $0.20 Granted 29,000,000 $0.002 Exercised - - Expired - - Outstanding, March 31, 2017 29,228,627 $0.004 The Company accounts for employee stock-based compensation in accordance with the guidance of ASC Topic 718: Compensation - Stock Compensation, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values The Company follows ASC Topic 505-50, formerly EITF 96-18, “Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling Goods and Services,” for stock options and warrants issued to consultants and other non-employees. In accordance with ASC Topic 505-50, these stock options issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option, whichever can be more clearly determined.

Commitments and Contigencies

Commitments and Contigencies	6 Months Ended	12 Months Ended
	Sep. 30, 2017	Mar. 31, 2017
Accounting Policies [Abstract]
Commitments and Contingencies	The Company leases office space on a verbal month-to-month agreement. Monthly rent is about $2,800. On July 8, 2016, the Company engaged a foreign based company to evaluate the safety and efficacy of RP-323 over a 27 month period. The contract stipulates a commitment of $193,255 with additional fees for pass-through expenses. The inventor of the intellectual property which was assigned to Rich Pharmaceuticals, Inc. in July 2013 by Imagic, LLC and Richard L. Chang’s Holdings, LLC is presently in declaratory relief litigation with Biosuccess Biotech, Co. LTD. (“Biosuccess”), a company who was previously assigned licensing rights in the intellectual property. In connection with this litigation, on January 17, 2014, the Company received notice of a complaint filed by Biosuccess against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (our CEO and a director) in the United States District Court, Central District of California Western Division (the “District Court”). The Complaint includes allegations of patent and copyright infringement, misappropriation of trade secrets, breach of fiduciary duty, unfair competition and other causes of actions against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (the “Litigation”). The Complaint seeks relief which includes compensatory damages, attorneys’ fees and costs, an award of treble damages, and such other relief as the court may deem just and proper. As previously disclosed on January 4, 2016, the Litigation has been settled through a confidential mediation process supervised by the Federal Court and the Litigation has been dismissed with prejudice by the Federal Court. The Company incurred substantial fees in defending the litigation. On April 1, 2017, the Company entered into a tentative agreement with CannCodex to issue 78,000,000 common shares of stock in exchange for data base assets of CannCodex. However, this agreement was not finalized and subsequently the Company is not responsible for issuance of the stock. Unrelated to this agreement, the Company has issued short-term loans to CannCodex totaling $15,300 as of September	The Company leases office space on a verbal month-to-month agreement. Monthly rent is approximately $2,800. On July 8, 2016, the Company engaged a foreign based company to evaluate the safety and efficacy of RP-323 over a 27 month period. The contract stipulates a commitment of $193,255 with additional fees for pass-through expenses. The inventor of the intellectual property which was assigned to Rich Pharmaceuticals, Inc. in July 2013 by Imagic, LLC and Richard L. Chang’s Holdings, LLC is presently in declaratory relief litigation with Biosuccess Biotech, Co. LTD. (“Biosuccess”), a company who was previously assigned licensing rights in the intellectual property. In connection with this litigation, on January 17, 2014, the Company received notice of a complaint filed by Biosuccess against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (our CEO and a director) in the United States District Court, Central District of California Western Division (the “District Court”). The Complaint includes allegations of patent and copyright infringement, misappropriation of trade secrets, breach of fiduciary duty, unfair competition and other causes of actions against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (the “Litigation”). The Complaint seeks relief which includes compensatory damages, attorneys’ fees and costs, an award of treble damages, and such other relief as the court may deem just and proper. As previously disclosed on January 4, 2016, the Litigation has been settled through a confidential mediation process supervised by the Federal Court and the Litigation has been dismissed with prejudice by the Federal Court. The Company incurred substantial fees in defending the litigation.

Liquidity and Going Concern

Liquidity and Going Concern	6 Months Ended	12 Months Ended
	Sep. 30, 2017	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	The Company has a working capital deficit, has not yet received significant revenues from sales of products or services, and has incurred losses since inception. These factors create substantial doubt about the Company’s ability to continue as a going concern for the twelve months following the date that these financial statements were issued. The financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company generating cash from the sale of its common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.	The Company has a working capital deficit, has not yet received revenues from sales of products or services, and has incurred losses since inception. These factors create substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company generating cash from the sale of its common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.

Income Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	As of March 31, 2017, the Company had net operating loss carry forwards of approximately $12,444,769 that may be available to reduce future years’ taxable income in varying amounts through 2034. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards. The provision for Federal income tax consists of the following for the years ended March 31, 2017 and 2016: March 31, 2017 March 31, 2016 Federal income tax benefit attributable to: Current operations $ 1,102,052 $ 601,276 Less: valuation allowance (1,102,052 ) (601,276 ) Net provision for Federal income taxes $ — $ — The cumulative tax effect at the expected rate of 34% of significant items comprising our net deferred tax amount is as follows as of March 31, 2017 and 2016: March 31, 2017 March 31, 2016 Deferred tax asset attributable to: Net operating loss carryover $ 4,231,221 $ 3,129,170 Less: valuation allowance (4,231,221 ) (3,129,170 ) Net deferred tax asset $ — $ — Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards of approximately $12,444,769 for Federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years.

Subsequent Events

Subsequent Events	6 Months Ended	12 Months Ended
	Sep. 30, 2017	Mar. 31, 2017
Accounting Policies [Abstract]
Subsequent Events	On November 3, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $34,500. The note bears interest at the rate of 10%, a 10% original issue discount and the lender will hold $1,500 to cover transaction costs, the note must be repaid by August 3, 2018. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or , On November 13, 2017, the Company entered into a consulting agreement for drug development services which calls for a fixed cost of $7,000 as work is completed and invoiced over the one year term of the agreement. On December 1, 2017, the Company extended the CEO’s employment agreement through November 2018. Subsequent to the period ended September 30, 2017 , the Company received, as listed, conversion notices from various note holders. The Company issued the following common shares to satisfy the conversion of the following debt and interest: Date Debt/Interest Converted Common Stock Issued Price per Share October 3, 2017 $10,931 43,900,000 $0.000249 October 5, 2017 $7,582 30,448,193 $0.000249 Subsequent Total $18,513 74,348,193 In accordance with ASC 855-10, the Company has analyzed its operations subsequent to September 30, 2017 to the date these financial statements were issued, and has determined that it does not have any material subsequent events to disclose in these financial statements other than the events described above.	On April 4, 2017, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $71,457, which refinances an unpaid convertible note dated January 22, 2016. The note bears interest at the rate of 8%, and must be repaid by January 4, 2018. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or , On April 5, 2017, the Company converted $6,004 in principle and $229 in interest on a convertible note payable into 5,300,000 shares of common stock. On April 10, 2017, the Company converted $6,363 in principle and $222 in interest on a convertible note payable into 5,600,000 shares of common stock. On April 11, 2017, the Company converted $6,004 in principle and $43 in interest on a convertible note payable into 5,850,000 shares of common stock. On April 18, 2017, the Company converted $7,000 in principle and $291 in interest on a convertible note payable into 6,200,000 shares of common stock. On April 18, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $115,000. The note bears interest at the rate of 10%, a 10% original issue discount and the lender will hold $5000 to cover transaction costs, the note must be repaid by January 30, 2018. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or , On April 20, 2017, the Company converted $7,564 in principle and $80 in interest on a convertible note payable into 6,500,000 shares of common stock. On April 21, 2017, the Company converted $16,426 in principle and $38 in interest on a convertible note payable into 14,000,000 shares of common stock. On April 25, 2017, the Company converted $17,148 in principle and $139 in interest on a convertible note payable into 14,700,000 shares of common stock. On April 26, 2017, the Company converted $25,000 in principle and $1,600 in interest on a convertible note payable into 26,600,000 shares of common stock. On May 1, 2017, the Company converted $8,514 in principle and $186 in interest on a convertible note payable into 14,500,000 shares of common stock. On May 9, 2017, the Company approved the reduction of the number of authorized $0.001 par value common stock from 40,000,000,000 common shares to 2,000,000,000 common shares. On May 15, 2017 the Company loaned $5,300 to a related party with a promissory note due in 1 year and stipulating a 0% interest rate. Effective June 7, 2017, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 20 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. On June 13, 2017, the Company converted $0 in principle and $1,200 in interest on a convertible note payable into 10,000,000 shares of common stock. On June 16, 2017, the Company converted $1,158 in principle and $142 in interest on a convertible note payable into 11,000,000 shares of common stock. On June 16, 2017, the Company converted $1,795 in principle and $135 in interest on a convertible note payable into 19,299,400 shares of common stock. On June 20, 2017, the Company converted $1,276 in principle and $116 in interest on a convertible note payable into 11,600,000 shares of common stock. On June 21, 2017, the Company converted $2,150 in principle and $164 in interest on a convertible note payable into 23,139,900 shares of common stock. On June 22, 2017, the Company converted $1,413 in principle and $57 in interest on a convertible note payable into 12,250,000 shares of common stock. On June 22, 2017, the Company converted $1,590 in principle and $0 in interest on a convertible note payable into 13,250,000 shares of common stock. On June 26, 2017, the Company converted $1,688 in principle and $112 in interest on a convertible note payable into 15,000,000 shares of common stock. On June 29, 2017, the Company converted $1,897 in principle and $83 in interest on a convertible note payable into 16,500,000 shares of common stock. On July 3, 2017, the Company converted $1,979 in principle and $109 in interest on a convertible note payable into 17,400,000 shares of common stock. On July 7, 2017, the Company entered into a two year consulting agreement with a related party. The agreement stipulates payment for scientific, clinical and regulatory services to the related party of $180,000 per year ($15,000 per month) with the option of common stock payment in lieu of cash. On July 11, 2017, Rich Pharmaceuticals, Inc. (the “Company”) entered into a Support and Collaboration Agreement (the “Collaboration Agreement”) with Mega Bridge, Inc., a Nevada corporation to be renamed “Hypgen”) (“Hypgen”), to support Hypgen’s development of treatments for Parkinson’s Disease. Under the terms of the agreement, the Company will provide data, raw materials and advisory support to Hypgen to assist Hypgen with their development of treatments for Parkinson’s Disease and the associated regulatory approval process. In exchange, Hypgen will pay the Company $100,000 and issue the Company 15,000,000 shares of Hypgen common stock. The Company plans to dividend five million of these shares to its shareholders at such time as the Company completes the necessary corporate and regulatory requirements regarding payment of a dividend. On July 12, 2017, the Company converted $0 in principle and $2,088 in interest on a convertible note payable into 17,400,000 shares of common stock. On July 13, 2017, the Company converted $1,344 in principle and $1,140 in interest on a convertible note payable into 13,800,000 shares of common stock. On July 14, 2017, the Company converted $3,358 in principle and $16 in interest on a convertible note payable into 19,000,000 shares of common stock. On July 3, 2017, the Company converted $3,314 in principle and $60 in interest on a convertible note payable into 19,000,000 shares of common stock. On July 20, 2017, the Company converted $3,554 in principle and $28 in interest on a convertible note payable into 19,900,000 shares of common stock. On July 24, 2017, the Company converted $6,217 in principle and $53 in interest on a convertible note payable into 20,900,000 shares of common stock. On July 25, 2017, the Company converted $6,022 in principle and $848 in interest on a convertible note payable into 22,900,000 shares of common stock. On July 28, 2017, the Company converted $7,089 in principle and $111 in interest on a convertible note payable into 24,000,000 shares of common stock. On August 2, 2017, the Company converted $7,035 in principle and $165 in interest on a convertible note payable into 24,000,000 shares of common stock. On August 4, 2017, the Company converted $8,942 in principle and $58 in interest on a convertible note payable into 25,000,000 shares of common stock. On August 8, 2017, the Company converted $11,022 in principle and $97 in interest on a convertible note payable into 26,475,000 shares of common stock. On August 11, 2017, the Company converted $13,920 of a convertible note payable into 29,000,000 shares of common stock. On August 16, 2017, the Company converted $12,810 of a convertible note payable into 30,500,000 shares of common stock. In accordance with ASC 855-10, the Company has analyzed its operations subsequent to March 31, 2017 to the date these financial statements were issued, and has determined that it does not have any material subsequent events to disclose in these financial statements other than the events described above.

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Policies)	6 Months Ended	12 Months Ended
	Sep. 30, 2017	Mar. 31, 2017
Accounting Policies [Abstract]
Nature of Business	On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”). On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 41,384 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000. On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 265,646 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 250,128 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 131,261 common shares. (All shares stated at post-split amounts.) On September 5, 2013, the Company increased the authorized common shares, par value $0.0010, from 900,000 shares to 375,030,000 shares. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. Effective June 7, 2017, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 20 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods.	On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”). On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 41,384 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000. On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 265,646 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 250,128 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 131,261 common shares. On September 5, 2013, the Company increased the authorized common shares, par value $0.0010, from 900,000 shares to 375,030,000 shares. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. Effective June 7, 2017, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 20 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods.
Cash and Cash Equivalents	The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At September 30, 2017 and March 31, 2017 the Company had $24,974 and $40,903, respectively, of unrestricted cash.	The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At March 31, 2017 and 2016 the Company had $40,903 and $-, respectively, of unrestricted cash.
Basis of Presentation	The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end. Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2017, as filed with the U.S. Securities and Exchange Commission.	The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end.
Property and Equipment	Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years.	Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years.
Long-Lived and Intangible Assets	On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 41,384 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. This asset was made accessible to a related party as part of a support and collaboration agreement dated July 11, 2017, in exchange for payment including 15,000,000 shares of the related parties common stock and cash of $100,000. This agreement does not diminish the Company’s ability to use or benefit from this asset. See note 3. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 110,396 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0. This asset was made accessible to a related party as part of a support and collaboration agreement dated July 11, 2017, in exchange for payment including 15,000,000 shares of the related parties common stock and cash of $100,000. This agreement does not diminish the Company’s ability to use or benefit from this asset. See note 3.	On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 41,384 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 110,396 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0.
Fair Value of Financial Instruments	The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value: Level 1 – Observable inputs such as quoted prices in active markets; Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company did not have any level 3 financial instruments at September 30, 2017 or March 31, 2017. As of September 30, 2017, the securities available for sale were considered a level 1 item (see note 3); the derivative liabilities were considered a level 2 item (see Note 9).	The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value: Level 1 – Observable inputs such as quoted prices in active markets; Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company did not have any level 1 or level 3 financial instruments at March 31, 2017 or March 31, 2016. As of March 31, 2017, the derivative liabilities were considered a level 2 item; see Note 8.
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The Company has made all adjustments necessary for a fair presentation of the interim financial information and all such adjustments are normal and recurring in nature, as required under ASC Topic 270.	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Income Taxes	Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.	Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.
Revenue Recognition	The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured.	The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured.
Research and Development	The Company will charge research and development costs to expense when incurred. The research and development costs include payments made to unrelated third party vendors for their work on enhancements to existing technology, or research into new potentially patentable products or processes.	The Company will charge research and development costs to expense when incurred. The research and development costs include payments made to unrelated third party vendors for their work on enhancements to existing technology, or research into new potentially patentable products or processes.
Stock-Based Compensation	Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 195,002 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 9,875 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 195,000 stock options to officers, directors, employees and consultants. During the period ended March 31, 2017, the Company granted 29,000,000 stock options to officers, directors, employees and consultants. The Company made the following modifications to the exercise prices of its options: January 12, 2015, the Company modified the exercise price on all outstanding stock options to $3.40; April 6, 2015, the Company modified the exercise price on all outstanding stock options to $1.60 per share; August 4, 2015, the Company modified the exercise price on all outstanding stock options to $0.20 per share. (All shares are stated at post-split amounts).	Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 195,002 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 9,875 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 195,000 stock options to officers, directors, employees and consultants. During the period ended March 31, 2017, the Company granted 29,000,000 stock options to officers, directors, employees and consultants. The Company made the following modifications to the exercise prices of its options: January 12, 2015, the Company modified the exercise price on all outstanding stock options to $3.40; April 6, 2015, the Company modified the exercise price on all outstanding stock options to $1.60 per share; August 4, 2015, the Company modified the exercise price on all outstanding stock options to $0.20 per share.
Basic loss per share	The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. Total potentially dilutive instruments are: 9,446,533 common share warrants, and 29,195,000 common shares upon exercise of outstanding options. In periods of net losses the dilutive loss per share is the same as the basic loss per share because the effect of the dilutive shares in periods of loss is antidilutive.	The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity.
Recent Accounting Pronouncements	The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.	The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

Property and equipment (Tables)

Property and equipment (Tables)	6 Months Ended	12 Months Ended
	Sep. 30, 2017	Mar. 31, 2017
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	September 30, 2017 March 31, 2017 Computer equipment & furniture $ 5,160 $ 5,160 Less: accumulated depreciation (3,622 ) (3,035 ) Property and equipment, net $ 1,538 $ 2,125	March 31, 2017 March 31, 2016 Computer equipment & furniture $ 5,160 $ 5,160 Less: accumulated depreciation (3,035 ) (1,429 ) Property and equipment, net $ 2,125 $ 3,731

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended	12 Months Ended
	Sep. 30, 2017	Mar. 31, 2017
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	September 30, 2017 March 31, 2017 Wages and taxes $ 1,012,457 $ 829,231 Accrued interest 176,063 108,552 Total accrued expenses $ 1,188,520 $ 937,783	March 31, 2017 March 31, 2016 Wages and taxes $ 829,231 $ 514,713 Accrued interest 108,552 15,437 Total accrued expenses $ 937,783 $ 530,150

Equity Transactions (Tables)

Equity Transactions (Tables)	1 Months Ended	6 Months Ended	12 Months Ended
	Oct. 31, 2017	Sep. 30, 2017	Mar. 31, 2017
Accounting Policies [Abstract]
Schedule of Value of Warrants		Date March 30, 2017 Warrants 9,200,000 Stock price on grant date $0.002 Exercise price $0.002 Expected life 5 year Volatility 120% Risk-free rate 1.96% Calculated value $15,278 Fair value allocation of proceeds $45,466	Date June 9, 2015 Dec 15,2015 March 30, 2017 Warrants 45,000 200,000 9,200,000 Stock price on grant date $0.40 $0.20 $0.002 Exercise price $0.40 $0.20 $0.002 Expected life 5 year 5 year 5 year Volatility 98% 98% 120% Risk-free rate 1.74% 1.71% 1.96% Calculated value $13,259 $29,612 $15,278 Fair value allocation of proceeds $13,259 $29,612 $45,466
Schedule of Warrant Activity		Number of warrants Weighted average exercise price Outstanding, March 31, 2017 9,446,533 $ 0.102 Granted — — Exercised — — Outstanding, September 30, 2017 9,446,533 $ 0.102	Number of warrants Weighted average exercise price Outstanding, March 31, 2016 246,533 $3.84 Granted 9,200,000 $0.002 Exercised - - Outstanding, March 31, 2017 9,446,556 $0.102
Schedule of Conversions of Common Stock	Date Debt/Interest Converted Common Stock Issued Price per Share October 3, 2017 $10,931 43,900,000 $0.000249 October 5, 2017 $7,582 30,448,193 $0.000249 Subsequent Total $18,513 74,348,193	Date Debt/Interest Converted Common Stock Issued Price per Share April 5, 2017 $6,233 5,300,000 $0.00118 April 10, 2017 $6,586 5,600,000 $0.00118 April 11, 2017 $6,880 5,850,000 $0.00118 April 18, 2017 $7,291 6,200,000 $0.00118 April 20, 2017 $7,644 6,500,000 $0.00118 April 21, 2017 $16,464 14,000,000 $0.00118 April 25, 2017 $17,287 14,700,000 $0.00118 April 26, 2017 $26,600 26,600,000 $0.00100 May 1, 2017 $8,700 14,500,000 $0.00060 June 13, 2017 $1,200 10,000,000 $0.00012 June 16, 2017 $1,930 19,299,400 $0.00010 June 16, 2017 $1,300 11,000,000 $0.00012 June 20, 2017 $1,392 11,600,000 $0.00012 June 21, 2017 $2,314 23,139,900 $0.00010 June 22, 2017 $1,590 13,250,000 $0.00012 June 22, 2017 $1,470 12,250,000 $0.00012 June 26, 2017 $1,800 15,000,000 $0.00012 June 29, 2017 $1,980 16,500,000 $0.00012 July 3, 2017 $2,088 17,400,000 $0.00012 July 12, 2017 $2,088 17,400,000 $0.00012 July 13, 2017 $2,484 13,800,000 $0.00018 July 14, 2017 $3,374 19,000,000 $0.00018 July 18, 2017 $3,374 19,000,000 $0.00018 July 20, 2017 $3,582 19,900,000 $0.00018 July 24, 2017 $6,270 20,900,000 $0.0003 July 25, 2017 $6,870 22,900,000 $0.0003 July 28, 2017 $7,200 24,000,000 $0.0003 August 2, 2017 $7,200 24,000,000 $0.0003 August 4, 2017 $9,000 25,000,000 $0.00036 August 8, 2017 $11,119 26,475,000 $0.00042 August 11, 2017 $13,920 29,000,000 $0.00048 August 16, 2017 $12,810 30,500,000 $0.00042 August 22, 2017 $6,709 19,168,058 $0.00035 August 25, 2017 $11,200 32,000,000 $0.00035 August 31, 2017 $9,600 32,000,000 $0.0003 September 7, 2017 $9,900 36,000,000 $0.00028 September 15, 2017 $9,437 37,900,000 $0.00025 September 22, 2017 $9,910 39,800,000 $0.00025 September 28, 2017 $10,408 41,800,000 $0.00025 September 30, 2017 Total $277,204 779,232,358	Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2015 $16,650 20,556 $0.81000 April 6, 2015 $10,000 10,482 $0.95400 April 8, 2015 $15,309 22,678 $0.67500 April 8, 2015 $20,001 22,727 $0.88000 April 9, 2015 $14,320 16,273 $0.88000 April 14, 2015 $10,000 11,848 $0.84400 April 16, 2015 $1,918 2,650 $0.72380 April 21, 2015 $10,000 12,987 $0.77000 April 29, 2015 $15,000 19,481 $0.77000 May 4, 2015 $5,083 6,573 $0.77320 May 12, 2015 $28,456 45,169 $0.63000 May 20, 2015 $20,199 47,382 $0.42620 May 20, 015 $17,240 39,182 $0.44000 May 27, 2015 $13,568 35,090 $0.38660 May 29, 2015 $15,000 44,118 $0.34000 June 11, 2015 $9,897 47,130 $0.21000 June 16, 2015 $14,100 58,750 $0.24000 June 16, 2015 $13,565 56,521 $0.24000 June 22, 2015 $7,415 61,792 $0.12000 June 22, 2015 $14,384 123,996 $0.11600 June 23, 2015 $7,752 64,600 $0.12000 September 16, 2015 $7,974 88,602 $0.09000 September 28, 2015 $10,000 83,333 $0.12000 September 29, 2015 $10,620 88,500 $0.12000 October 7, 2015 $2,250 18,750 $0.12000 October 7, 2015 $8,400 70,000 $0.12000 October 19, 2015 $9,720 81,000 $0.12000 November 2, 2015 $4,424 98,306 $0.04500 November 23, 2015 $10,000 83,333 $0.12000 November 30, 2015 $16,844 129,566 $0.13000 December 9, 2015 $1,746 38,800 $0.04500 December 17, 2015 $5,332 45,966 $0.11600 December 28, 2015 $1,341 29,810 $0.04500 December 28, 2015 $17,700 147,500 $0.12000 December 28, 2015 $14,305 119,208 $0.12000 December 28, 2015 $14,963 128,996 $0.11600 December 29, 2015 $8,395 69,958 $0.12000 December 29, 2015 $7,670 63,917 $0.12000 December 30, 2015 $6,651 147,812 $0.04500 January 1, 2016 $28,500 219,231 $0.13000 January 4, 2016 $19,339 161,161 $0.12000 January 5, 2016 $8,107 180,161 $0.04500 January 6, 2016 $16,070 133,917 $0.12000 January 6, 2016 $16,597 143,080 $0.11600 February 16 ,2016 $1,424 211,020 $0.00680 February 17, 2016 $12,800 422,164 $0.03040 February 23, 2016 $4,640 210,909 $0.02200 February 23, 2016 $3,086 210,044 $0.01460 February 24, 2016 $1,492 220,999 $0.00680 February 25, 2016 $3,000 131,949 $0.02280 February 25, 2016 $4,640 210,909 $0.02200 March 1, 2016 $1,313 291,723 $0.00440 March 2, 2016 $4,600 291,582 $0.01580 March 2, 2016 $1,650 129,321 $0.01280 March 2, 2016 $9,332 582,500 $0.01600 March 7, 2016 $2,799 327,315 $0.00860 March 11, 2016 $1,924 207,375 $0.00920 March 14, 2016 $2,245 356,289 $0.00640 March 15, 2016 $3,329 372,705 $0.00900 March 15, 2016 $5,210 572,500 $0.00920 March 22, 2016 $2,419 447,894 $0.00540 March 22, 2016 $2,367 360,023 $0.00660 March 22, 2016 $5,315 584,100 $0.00920 March 28, 2016 $1,986 447,939 $0.00440 March 31, 2016 Total $602,376 9,730,152 Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2016 $2,197 488,316 $ 0.00450 April 4, 2016 $4,847 862,500 $ 0.00562 April 7, 2016 $1,750 486,111 $ 0.00360 April 14, 2016 $4,158 962,500 $ 0.00432 April 15, 2016 $1,318 488,311 $ 0.00270 April 26, 2016 $1,705 631,489 $ 0.00270 May 4, 2016 $2,067 485,901 $ 0.00426 May 31, 2016 $ 828 230,003 $ 0.00360 June 2, 2016 $9,120 1,500,000 $ 0.00608 June 2, 2016 $4,401 1,467,017 $ 0.00300 June 14, 2016 $5,847 1,461,795 $ 0.00400 June 17,2016 $5,691 1,422,808 $ 0.00400 June 29, 2016 $6,580 1,063,518 $ 0.00618 August 23, 2016 $2,567 1,106,487 $ 0.00232 August 29, 2016 $2,570 1,107,806 $ 0.00232 September 6, 2016 $2,547 1,097,634 $ 0.00232 September 20, 2016 $2,443 1,263,383 $ 0.00194 September 26, 2016 $2,946 1,269,672 $ 0.00232 September 28, 2016 $2,947 1,270,172 $ 0.00232 September 30, 2016 $3,949 2,553,336 $ 0.00154 October 7, 2016 $3,381 2,914,578 $ 0.00116 October 14, 2016 $3,380 2,913,784 $ 0.00116 October 21, 2016 $3,385 2,917,784 $ 0.00116 October 26, 2016 $3,382 2,915,828 $ 0.00116 October 31, 2016 $5,037 4,341,852 $ 0.00116 November 7 , 2016 $5,015 4,323,647 $ 0.00116 November 22, 2016 $5,513 4,753,008 $ 0.00116 November 29, 2016 $5,515 4,754,647 $ 0.00116 December 6, 2016 $4,058 3,497,965 $ 0.00116 January 10, 2017 $6,301 6,301,150 $ 0.00100 February 22, 2017 $4,290 3,575,000 $ 0.00120 March 13, 2017 $4,080 3,400,000 $ 0.00120 March 21, 2017 $4,920 4,100,000 $ 0.00120 March 22, 2017 $5,160 4,300,000 $ 0.00120 March 24, 2017 $5,460 4,550,000 $ 0.00120 March 30, 2017 $5,645 4,800,000 $ 0.00118 March 31, 2017 $5,939 5,050,000 $ 0.00118 March 31, 2017 Total $150,939 90,628,002
Schedule of Value of Options		Date April 6, 2015 June 9, 2015 December 15, 2015 March 30, 2017 Options 102,000 50,000 43,000 29,000,000 Stock price grant date $1.60 $0.40 $0.20 $0.002 Initial Exercise price $1.60 $0.40 $0.20 $0.002 Modified Exercise price $0.20 $0.20 $0.20 - Expected life 5.0 5.0 5.0 5.0 Volatility 99% 99% 84% 120% Risk-free rate 1.31% 1.74% 1.70% 1.93% Calculated value $120,778 $14,838 $5,736 $48,017 Modified value $151,221 $16,347 $5,736 $48,017	Date April 6, 2015 June 9, 2015 December 15, 2015 March 30, 2017 Options 102,000 50,000 43,000 29,000,000 Stock price grant date $1.60 $0.40 $0.20 $0.002 Initial Exercise price $1.60 $0.40 $0.20 $0.002 Modified Exercise price $0.20 $0.20 $0.20 - Expected life 5.0 5.0 5.0 5.0 Volatility 99% 99% 84% 120% Risk-free rate 1.31% 1.74% 1.70% 1.93% Calculated value $120,778 $14,838 $5,736 $48,017 Modified value $151,221 $16,347 $5,736 $48,017
Schedule of Option Activity		Number of options Weighted average exercise price Outstanding, March 31, 2017 29,228,627 $ 0.004 Granted — — Exercised — — Expired — — Outstanding, September 29,228,627 $ 0.004	Number of options Weighted average exercise price Outstanding, March 31, 2016 228,627 $0.20 Granted 29,000,000 $0.002 Exercised - - Expired - - Outstanding, March 31, 2017 29,228,627 $0.004

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Federal Income Tax	March 31, 2017 March 31, 2016 Federal income tax benefit attributable to: Current operations $ 1,102,052 $ 601,276 Less: valuation allowance (1,102,052 ) (601,276 ) Net provision for Federal income taxes $ — $ —
Schedule of Deferred Tax Asset	March 31, 2017 March 31, 2016 Deferred tax asset attributable to: Net operating loss carryover $ 4,231,221 $ 3,129,170 Less: valuation allowance (4,231,221 ) (3,129,170 ) Net deferred tax asset $ — $ —

Subsequent Events (Tables)

Subsequent Events (Tables)	1 Months Ended	6 Months Ended	12 Months Ended
	Oct. 31, 2017	Sep. 30, 2017	Mar. 31, 2017
Subsequent Events Tables
Schedule of Conversions of Common Stock	Date Debt/Interest Converted Common Stock Issued Price per Share October 3, 2017 $10,931 43,900,000 $0.000249 October 5, 2017 $7,582 30,448,193 $0.000249 Subsequent Total $18,513 74,348,193	Date Debt/Interest Converted Common Stock Issued Price per Share April 5, 2017 $6,233 5,300,000 $0.00118 April 10, 2017 $6,586 5,600,000 $0.00118 April 11, 2017 $6,880 5,850,000 $0.00118 April 18, 2017 $7,291 6,200,000 $0.00118 April 20, 2017 $7,644 6,500,000 $0.00118 April 21, 2017 $16,464 14,000,000 $0.00118 April 25, 2017 $17,287 14,700,000 $0.00118 April 26, 2017 $26,600 26,600,000 $0.00100 May 1, 2017 $8,700 14,500,000 $0.00060 June 13, 2017 $1,200 10,000,000 $0.00012 June 16, 2017 $1,930 19,299,400 $0.00010 June 16, 2017 $1,300 11,000,000 $0.00012 June 20, 2017 $1,392 11,600,000 $0.00012 June 21, 2017 $2,314 23,139,900 $0.00010 June 22, 2017 $1,590 13,250,000 $0.00012 June 22, 2017 $1,470 12,250,000 $0.00012 June 26, 2017 $1,800 15,000,000 $0.00012 June 29, 2017 $1,980 16,500,000 $0.00012 July 3, 2017 $2,088 17,400,000 $0.00012 July 12, 2017 $2,088 17,400,000 $0.00012 July 13, 2017 $2,484 13,800,000 $0.00018 July 14, 2017 $3,374 19,000,000 $0.00018 July 18, 2017 $3,374 19,000,000 $0.00018 July 20, 2017 $3,582 19,900,000 $0.00018 July 24, 2017 $6,270 20,900,000 $0.0003 July 25, 2017 $6,870 22,900,000 $0.0003 July 28, 2017 $7,200 24,000,000 $0.0003 August 2, 2017 $7,200 24,000,000 $0.0003 August 4, 2017 $9,000 25,000,000 $0.00036 August 8, 2017 $11,119 26,475,000 $0.00042 August 11, 2017 $13,920 29,000,000 $0.00048 August 16, 2017 $12,810 30,500,000 $0.00042 August 22, 2017 $6,709 19,168,058 $0.00035 August 25, 2017 $11,200 32,000,000 $0.00035 August 31, 2017 $9,600 32,000,000 $0.0003 September 7, 2017 $9,900 36,000,000 $0.00028 September 15, 2017 $9,437 37,900,000 $0.00025 September 22, 2017 $9,910 39,800,000 $0.00025 September 28, 2017 $10,408 41,800,000 $0.00025 September 30, 2017 Total $277,204 779,232,358	Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2015 $16,650 20,556 $0.81000 April 6, 2015 $10,000 10,482 $0.95400 April 8, 2015 $15,309 22,678 $0.67500 April 8, 2015 $20,001 22,727 $0.88000 April 9, 2015 $14,320 16,273 $0.88000 April 14, 2015 $10,000 11,848 $0.84400 April 16, 2015 $1,918 2,650 $0.72380 April 21, 2015 $10,000 12,987 $0.77000 April 29, 2015 $15,000 19,481 $0.77000 May 4, 2015 $5,083 6,573 $0.77320 May 12, 2015 $28,456 45,169 $0.63000 May 20, 2015 $20,199 47,382 $0.42620 May 20, 015 $17,240 39,182 $0.44000 May 27, 2015 $13,568 35,090 $0.38660 May 29, 2015 $15,000 44,118 $0.34000 June 11, 2015 $9,897 47,130 $0.21000 June 16, 2015 $14,100 58,750 $0.24000 June 16, 2015 $13,565 56,521 $0.24000 June 22, 2015 $7,415 61,792 $0.12000 June 22, 2015 $14,384 123,996 $0.11600 June 23, 2015 $7,752 64,600 $0.12000 September 16, 2015 $7,974 88,602 $0.09000 September 28, 2015 $10,000 83,333 $0.12000 September 29, 2015 $10,620 88,500 $0.12000 October 7, 2015 $2,250 18,750 $0.12000 October 7, 2015 $8,400 70,000 $0.12000 October 19, 2015 $9,720 81,000 $0.12000 November 2, 2015 $4,424 98,306 $0.04500 November 23, 2015 $10,000 83,333 $0.12000 November 30, 2015 $16,844 129,566 $0.13000 December 9, 2015 $1,746 38,800 $0.04500 December 17, 2015 $5,332 45,966 $0.11600 December 28, 2015 $1,341 29,810 $0.04500 December 28, 2015 $17,700 147,500 $0.12000 December 28, 2015 $14,305 119,208 $0.12000 December 28, 2015 $14,963 128,996 $0.11600 December 29, 2015 $8,395 69,958 $0.12000 December 29, 2015 $7,670 63,917 $0.12000 December 30, 2015 $6,651 147,812 $0.04500 January 1, 2016 $28,500 219,231 $0.13000 January 4, 2016 $19,339 161,161 $0.12000 January 5, 2016 $8,107 180,161 $0.04500 January 6, 2016 $16,070 133,917 $0.12000 January 6, 2016 $16,597 143,080 $0.11600 February 16 ,2016 $1,424 211,020 $0.00680 February 17, 2016 $12,800 422,164 $0.03040 February 23, 2016 $4,640 210,909 $0.02200 February 23, 2016 $3,086 210,044 $0.01460 February 24, 2016 $1,492 220,999 $0.00680 February 25, 2016 $3,000 131,949 $0.02280 February 25, 2016 $4,640 210,909 $0.02200 March 1, 2016 $1,313 291,723 $0.00440 March 2, 2016 $4,600 291,582 $0.01580 March 2, 2016 $1,650 129,321 $0.01280 March 2, 2016 $9,332 582,500 $0.01600 March 7, 2016 $2,799 327,315 $0.00860 March 11, 2016 $1,924 207,375 $0.00920 March 14, 2016 $2,245 356,289 $0.00640 March 15, 2016 $3,329 372,705 $0.00900 March 15, 2016 $5,210 572,500 $0.00920 March 22, 2016 $2,419 447,894 $0.00540 March 22, 2016 $2,367 360,023 $0.00660 March 22, 2016 $5,315 584,100 $0.00920 March 28, 2016 $1,986 447,939 $0.00440 March 31, 2016 Total $602,376 9,730,152 Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2016 $2,197 488,316 $ 0.00450 April 4, 2016 $4,847 862,500 $ 0.00562 April 7, 2016 $1,750 486,111 $ 0.00360 April 14, 2016 $4,158 962,500 $ 0.00432 April 15, 2016 $1,318 488,311 $ 0.00270 April 26, 2016 $1,705 631,489 $ 0.00270 May 4, 2016 $2,067 485,901 $ 0.00426 May 31, 2016 $ 828 230,003 $ 0.00360 June 2, 2016 $9,120 1,500,000 $ 0.00608 June 2, 2016 $4,401 1,467,017 $ 0.00300 June 14, 2016 $5,847 1,461,795 $ 0.00400 June 17,2016 $5,691 1,422,808 $ 0.00400 June 29, 2016 $6,580 1,063,518 $ 0.00618 August 23, 2016 $2,567 1,106,487 $ 0.00232 August 29, 2016 $2,570 1,107,806 $ 0.00232 September 6, 2016 $2,547 1,097,634 $ 0.00232 September 20, 2016 $2,443 1,263,383 $ 0.00194 September 26, 2016 $2,946 1,269,672 $ 0.00232 September 28, 2016 $2,947 1,270,172 $ 0.00232 September 30, 2016 $3,949 2,553,336 $ 0.00154 October 7, 2016 $3,381 2,914,578 $ 0.00116 October 14, 2016 $3,380 2,913,784 $ 0.00116 October 21, 2016 $3,385 2,917,784 $ 0.00116 October 26, 2016 $3,382 2,915,828 $ 0.00116 October 31, 2016 $5,037 4,341,852 $ 0.00116 November 7 , 2016 $5,015 4,323,647 $ 0.00116 November 22, 2016 $5,513 4,753,008 $ 0.00116 November 29, 2016 $5,515 4,754,647 $ 0.00116 December 6, 2016 $4,058 3,497,965 $ 0.00116 January 10, 2017 $6,301 6,301,150 $ 0.00100 February 22, 2017 $4,290 3,575,000 $ 0.00120 March 13, 2017 $4,080 3,400,000 $ 0.00120 March 21, 2017 $4,920 4,100,000 $ 0.00120 March 22, 2017 $5,160 4,300,000 $ 0.00120 March 24, 2017 $5,460 4,550,000 $ 0.00120 March 30, 2017 $5,645 4,800,000 $ 0.00118 March 31, 2017 $5,939 5,050,000 $ 0.00118 March 31, 2017 Total $150,939 90,628,002

Summary of Significant Accoun29

Summary of Significant Accounting Policies (Details Narrative)	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Sep. 30, 2017USD ($)$ / sharesshares	Mar. 31, 2017USD ($)$ / sharesshares	Mar. 31, 2016USD ($)$ / sharesshares	Mar. 31, 2015shares	Mar. 31, 2014shares	Mar. 31, 2013$ / sharesshares	May 09, 2017$ / sharesshares	Sep. 06, 2013$ / sharesshares	Sep. 05, 2013$ / sharesshares
Date Of Incorporation		Aug. 9, 2010	Aug. 9, 2010
Cancellation of loans | $
Common Stock, Shares Authorized		2,000,000,000	2,000,000,000	2,000,000,000			375,030,000	2,000,000,000	375,030,000	900,000
Common Stock, Par Value | $ / shares		$ .001	$ 0.001	$ 0.001			$ 0.001	$ 0.001	$ 0.001	$ 0.001
Stock split ratio	0.05	0.05	0.05	0.01			4.1671
Cash and cash equivalent | $		$ 24,974	$ 40,903
Reserved common shares			195,002						195,002
Computer equipment		3 years	3 years
Options granted, number of shares			29,000,000	195,000	9,875	23,752
Options, exercise price | $ / shares			$ 0.001
Dilutive Instruments, common stock warrants		9,446,533
Dilutive Instruments, common stock shares		29,195,000
Sale Agmt
Date of Agreement		Jul. 19, 2013	Jul. 19, 2013
Cancellation of loans | $		$ 28,818	$ 28,818
Shares sold by former officers		265,646	265,646
Shares returned to treasury		250,128	250,128
Shares agreed to cancel		131,261	131,261
Asset Assign Agmt
Date of Agreement		Jul. 18, 2013	Jul. 18, 2013
Common Stock, shares issued		41,384	41,384
Series A Preferred Stock, shares issued		6,000,000	6,000,000
Stock Value | $		$ 123,973	$ 123,973
Termination of agreement | $		20,000	20,000
Additional cash required | $		$ 2,000,000	$ 2,000,000

Summary of Significant Accoun30

Summary of Significant Accounting Policies (Details Narrative) 12M	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Sep. 30, 2017USD ($)$ / sharesshares	Mar. 31, 2017USD ($)$ / sharesshares	Mar. 31, 2016USD ($)$ / sharesshares	Mar. 31, 2015USD ($)shares	Mar. 31, 2014USD ($)shares	Mar. 31, 2013$ / sharesshares	May 09, 2017$ / sharesshares	Sep. 06, 2013$ / sharesshares	Sep. 05, 2013$ / sharesshares
Date Of Incorporation		Aug. 9, 2010	Aug. 9, 2010
Cancellation of loans | $
Common Stock, Shares Authorized		2,000,000,000	2,000,000,000	2,000,000,000			375,030,000	2,000,000,000	375,030,000	900,000
Common Stock, Par Value | $ / shares		$ .001	$ 0.001	$ 0.001			$ 0.001	$ 0.001	$ 0.001	$ 0.001
Stock split ratio	0.05	0.05	0.05	0.01			4.1671
Cash and cash equivalent | $		$ 24,974	$ 40,903
Intangible assets | $			$ 0
Impairment of intangible asset | $				$ 0	$ 82,120	$ 0
Reserved common shares			195,002						195,002
Stock options granted			29,000,000	195,000	9,875
Computer equipment		3 years	3 years
Options granted, number of shares			29,000,000	195,000	9,875	23,752
Options, exercise price | $ / shares			$ 0.001
Sale Agmt
Date of Agreement		Jul. 19, 2013	Jul. 19, 2013
Cancellation of loans | $		$ 28,818	$ 28,818
Shares sold by former officers		265,646	265,646
Shares returned to treasury		250,128	250,128
Shares agreed to cancel		131,261	131,261
Asset Assign Agmt
Date of Agreement		Jul. 18, 2013	Jul. 18, 2013
Common Stock, shares issued		41,384	41,384
Series A Preferred Stock, shares issued		6,000,000	6,000,000
Stock Value | $		$ 123,973	$ 123,973
Termination of agreement | $		20,000	20,000
Additional cash required | $		$ 2,000,000	$ 2,000,000

Property and equipment - Schedu

Property and equipment - Schedule of Property and Equipment (Details) - USD ($)	Sep. 30, 2017	Mar. 31, 2017	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Computer equipment	$ 5,160	$ 5,160	$ 5,160
Less: accumulated depreciation	(3,622)	(3,035)	(1,429)
Property and equipment, net	$ 1,538	$ 2,125	$ 3,731

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Mar. 31, 2017	Mar. 31, 2016
Property And Equipment Details Narrative
Depreciation expense	$ 313	$ 431	$ 586	$ 863	$ 1,606	$ 799
Computer equipment			3 years		3 years

Securities Available For Sale (

Securities Available For Sale (Details Narrative) - Collaboration Agmt	Sep. 30, 2017shares
Securities available for sale	15,000,000
Ownership of Subsidiary	11.00%

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Sep. 30, 2017	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Impairment of intangible asset				$ 0	$ 82,120	$ 0
Collaboration Agmt
Date of Agreement	Jul. 11, 2017	Jul. 11, 2017
Securities available for sale		15,000,000
Payment for IP		$ 100,000
Asset Assign Agmt
Date of Agreement		Jul. 18, 2013	Jul. 18, 2013
Common Stock, shares issued		41,384	41,384
Series A Preferred Stock, shares issued		6,000,000	6,000,000
Stock Value		$ 123,973	$ 123,973
Impaired Assets		0
Asset Development Cost		$ 45,000
Asset Assign Agmt #2
Date of Agreement		Oct. 6, 2014	Oct. 6, 2014
Common Stock, shares issued		110,396	110,396
Common stock, value		$ 7,904,355	$ 7,904,355
Impaired Assets		0	0
Impairment of intangible asset		$ 82,120	$ 82,120

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Sep. 30, 2017	Mar. 31, 2017	Mar. 31, 2016
Payables and Accruals [Abstract]
Wages and taxes	$ 1,012,457	$ 829,231	$ 514,713
Accrued interest	176,063	108,552	15,437
Total accrued expenses	$ 1,188,520	$ 937,783	$ 530,150

Related Party Debt and Transa36

Related Party Debt and Transactions (Details Narrative) - USD ($)	3 Months Ended			6 Months Ended		12 Months Ended
	Sep. 30, 2017	Jun. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015	May 15, 2017
Cancellation of loans
Due to related parties	$ 54,001			54,001		49,395
Loans and interest received (repaid) from/to related parties				4,606	$ (37,812)	(27,518)	$ 70,846
Interest expense, related party	(155)		$ (155)	(308)	$ (230)	(536)	(300)
Accrued expenses	1,188,520			1,188,520		937,783	530,150
Accounts payable related party	286,700			286,700		53,000
SH Loan #1
Due Date								Jan. 8, 2016
Loan from related party								$ 6,000
Interest Rate								8.00%
SH Loan #2
Loan from related party				6,280		6,280
Due to related parties	$ 12,280			$ 12,280		$ 12,280
Interest Rate	8.00%			8.00%		8.00%
Interest expense, related party				$ 1,211		$ 903	267
Related Party Loans
Due Date		May 15, 2018
Due to related parties	$ 350			350
Repayment of loans to related parties				40,160		36,300
Loans and interest received (repaid) from/to related parties				$ 36,300
Accrued expenses						$ 14,450	22,200		$ 5,300
Employment Agmt
Date of Agreement				Sep. 6, 2013		Sep. 6, 2013
Term of Agreement				2 years		2 years
Annual Compensation				$ 275,000		$ 275,000
Options to purchase				1,500		1,500
Options to purchase, exercise price				$ 40		$ 40
Bonus				$ 137,500		$ 68,750
Earnings				275,000		275,000	275,000
Accrued Earnings				$ 737,611		$ 645,945	$ 395,630
Collaboration Agmt
Date of Agreement		Jul. 11, 2017		Jul. 11, 2017
Securities available for sale	15,000,000			15,000,000
Payment for IP				$ 100,000

Related Party Debt and Transa37

Related Party Debt and Transactions (Details Narrative) 12M - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015	May 15, 2017
Cancellation of loans
Due to related parties	$ 54,001		54,001		49,395
Loans and interest received (repaid) from/to related parties			4,606	$ (37,812)	(27,518)	$ 70,846
Interest expense, related party	(155)	$ (155)	(308)	$ (230)	(536)	(300)
Accrued expenses	1,188,520		1,188,520		937,783	530,150
SH Loan #1
Loan from related party							$ 6,000
Interest Rate							8.00%
SH Loan #2
Loan from related party			6,280		6,280
Due to related parties	$ 12,280		$ 12,280		$ 12,280
Interest Rate	8.00%		8.00%		8.00%
Interest expense, related party			$ 1,211		$ 903	267
Related Party Loans
Due to related parties	$ 350		350
Repayment of loans to related parties			40,160		36,300
Loans and interest received (repaid) from/to related parties			$ 36,300
Accrued expenses					14,450	22,200		$ 5,300
Accrued expenses, balance due					$ 350
Employment Agmt
Date of Agreement			Sep. 6, 2013		Sep. 6, 2013
Term of Agreement			2 years		2 years
Annual Compensation			$ 275,000		$ 275,000
Options to purchase			1,500		1,500
Options to purchase, exercise price			$ 40		$ 40
Bonus			$ 137,500		$ 68,750
Earnings			275,000		275,000	275,000
Accrued Earnings			$ 737,611		$ 645,945	$ 395,630

Note Payable (Details Narrative

Note Payable (Details Narrative) - USD ($)	6 Months Ended	12 Months Ended
	Sep. 30, 2017	Mar. 31, 2017
Note Payable #1
Date of Agreement	May 31, 2016	Aug. 13, 2014
Convertible Note	$ 900,000	$ 900,000
Interest Rate	10.00%	10.00%
Due Date	Aug. 1, 2017	Aug. 1, 2017
Interest Accrued	$ 120,082	$ 74,959
Note Payable #2
Date of Agreement	Feb. 21, 2017	Feb. 21, 2017
Convertible Note	$ 20,000	$ 20,000
Interest Rate	8.00%	8.00%
Due Date	Aug. 21, 2017	Aug. 21, 2017
Interest Accrued	$ 969	$ 167

Convertible Note Payable (Detai

Convertible Note Payable (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2017	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Mar. 31, 2017	Mar. 31, 2016
Debt Instrument, Converted Amount			$ 277,208	$ 70,478	$ 389,100	$ 602,374
Debt Instrument, Interest Accrued, Converted Amount					11,010
Convertible Prom Note #15
Date of Agreement						Feb. 5, 2015
Convertible Note						$ 54,000
Interest Rate						8.00%
Due Date						Nov. 9, 2015
Interest Accrued			0
Convertible Note, Balance			0		$ 59,799	$ 47,980
Debt Instrument, Converted Amount						$ 33,020
Common Stock, shares issued						619,652
Fee					Financing	Default
Fee Amount		$ 11,819			$ 11,819	$ 27,000
Convertible Prom Note #18
Date of Agreement						Mar. 9, 2015
Convertible Note						$ 55,000
Interest Rate						8.00%
Due Date						Jun. 23, 2017
Interest Accrued				0	0	$ 0
Convertible Note, Balance				8,838	0	16,215
Debt Instrument, Converted Amount				7,377		38,785
Debt Instrument, Interest Accrued, Converted Amount				$ 422		$ 5,135
Common Stock, shares issued				2,324,229		2,886,693
Convertible Prom Note #19
Date of Agreement				Mar. 26, 2015
Convertible Note				$ 29,680
Interest Rate				8.00%
Due Date				Mar. 23, 2016
Interest Accrued			4,602	$ 2,577
Convertible Note, Balance				18,751
Original Issue Discount				1,680
Debt Instrument, Converted Amount				$ 10,929
Common Stock, shares issued				796,236
Convertible Prom Note #21
Date of Agreement				May 5, 2015
Convertible Note				$ 68,900
Interest Rate				8.00%
Due Date				May 5, 2016
Interest Accrued					0
Convertible Note, Balance					0
Original Issue Discount				$ 3,900
Debt Instrument, Converted Amount				8,461	60,439
Debt Instrument, Interest Accrued, Converted Amount				$ 566	$ 6,839
Common Stock, shares issued				906,763	44,551,004
Convertible Prom Note #22
Date of Agreement					May 6, 2015
Convertible Note					$ 10,500
Interest Rate					8.00%
Due Date					Feb. 8, 2016
Interest Accrued			0
Convertible Note, Balance		$ 20,900	0		$ 15,750
Fee		Financing			Default
Fee Amount		$ 5,250	$ 5,150		$ 5,250
Convertible Prom Note #24
Date of Agreement					Aug. 28, 2015
Convertible Note					$ 15,000
Interest Rate					8.00%
Due Date					Aug. 28, 2016
Interest Accrued					$ 0
Convertible Note, Balance					0
Debt Instrument, Converted Amount					15,000
Debt Instrument, Interest Accrued, Converted Amount					$ 939
Common Stock, shares issued					4,351,619
Convertible Prom Note #25
Date of Agreement					Sep. 4, 2015
Convertible Note					$ 19,000
Interest Rate					8.00%
Due Date					Jun. 4, 2016
Interest Accrued		0
Convertible Note, Balance		0			$ 20,280
Fee					Financing
Fee Amount		1,280			$ 1,280
Convertible Prom Note #26
Date of Agreement						Dec. 29, 2015
Convertible Note						$ 57,378
Interest Rate						8.00%
Due Date						Jun. 23, 2017
Interest Accrued					0	$ 0
Convertible Note, Balance					$ 0	1,609
Debt Instrument, Converted Amount						59,934
Debt Instrument, Interest Accrued, Converted Amount						$ 1,222
Common Stock, shares issued						1,796,394
Fee						Default
Fee Amount						$ 4,165
Convertible Prom Note #27
Date of Agreement			Jan. 22, 2016
Convertible Note			$ 60,500
Interest Rate			10.00%
Due Date			Oct. 22, 2016
Interest Accrued			$ 0
Convertible Note, Balance			$ 0
Convertible Prom Note #28
Date of Agreement					Feb. 25, 2016
Convertible Note					$ 27,500
Interest Rate					8.00%
Due Date					Feb. 25, 2017
Interest Accrued					$ 0
Convertible Note, Balance					0
Original Issue Discount, unamortized					212
Debt Instrument, Converted Amount					16,745
Debt Instrument, Interest Accrued, Converted Amount					$ 1,380
Common Stock, shares issued					3,325,000
Convertible Prom Note #29
Date of Agreement					Mar. 24, 2016
Convertible Note					$ 7,500
Interest Rate					8.00%
Due Date					Mar. 24, 2017
Interest Accrued					$ 0
Convertible Prom Note #34
Date of Agreement					May 25, 2016
Convertible Note					$ 30,000
Interest Rate					8.00%
Due Date					May 25, 2017
Interest Accrued					$ 0
Convertible Note, Balance					$ 0
Fee					Financing
Fee Amount		8,107			$ 8,107
Convertible Prom Note #30
Date of Agreement					Jun. 8, 2016
Convertible Note					$ 84,250
Interest Rate					8.00%
Due Date					Jun. 8, 2017
Interest Accrued					$ 0
Convertible Note, Balance					$ 0
Fee					Financing
Fee Amount		$ 49,964			$ 49,964
Convertible Prom Note #32
Date of Agreement			Jun. 23, 2016
Convertible Note			$ 56,000
Interest Rate			8.00%
Due Date			Jun. 23, 2017
Interest Accrued			$ 5,695
Convertible Prom Note #35
Date of Agreement			Jul. 7, 2016
Convertible Note			$ 58,000
Interest Rate			8.00%
Due Date			Jul. 7, 2017
Interest Accrued			$ 2,869
Convertible Note, Balance			29,055
Debt Instrument, Converted Amount			28,945
Debt Instrument, Interest Accrued, Converted Amount			$ 1,902
Common Stock, shares issued			69,039,300
Convertible Prom Note #36
Date of Agreement			Oct. 20, 2016
Convertible Note			$ 32,000
Interest Rate			8.00%
Due Date			Oct. 20, 2017
Interest Accrued			$ 2,420
Convertible Prom Note #37
Date of Agreement			Nov. 17, 2016
Convertible Note			$ 56,000
Interest Rate			8.00%
Due Date			Jun. 23, 2017
Interest Accrued			$ 5,695
Convertible Prom Note #38
Date of Agreement			Jan. 5, 2017
Convertible Note			$ 335,000
Interest Rate			10.00%
Due Date			Oct. 5, 2017
Interest Accrued			$ 23,310
Convertible Note, Balance			0
Original Issue Discount			30,000
Convertible Prom Note #39
Date of Agreement					Feb. 20, 2017
Convertible Note					$ 563,028
Interest Rate					8.00%
Due Date					Oct. 25, 2017
Interest Accrued			3,297		$ 904
Convertible Note, Balance			122,086		124,066
Debt Instrument, Converted Amount			86,857		34,370
Debt Instrument, Interest Accrued, Converted Amount			$ 3,048		$ 1,124
Common Stock, shares issued			179,650,000		29,775,000
Convertible Prom Note #40
Date of Agreement			Feb. 21, 2017
Convertible Note			$ 15,000
Interest Rate			8.00%
Due Date			Oct. 25, 2017
Interest Accrued			$ 727
Convertible Prom Note #41
Date of Agreement			Feb. 22, 2017
Convertible Note			$ 59,799
Interest Rate			10.00%
Due Date			Oct. 25, 2017
Convertible Note, Balance			$ 0
Debt Instrument, Converted Amount			59,799
Debt Instrument, Interest Accrued, Converted Amount			4,795
Default Penalty to be recognized			$ 31,407
Common Stock, shares issued			311,043,058
Default Penalty to be recognized			$ 31,407
Convertible Prom Note #42
Date of Agreement			Feb. 22, 2017
Convertible Note			$ 20,900
Interest Rate			10.00%
Due Date			Oct. 22, 2017
Interest Accrued			$ 49
Convertible Note, Balance			13,207
Debt Instrument, Converted Amount			7,693
Debt Instrument, Interest Accrued, Converted Amount			18,607
Default Penalty to be recognized			$ 34,156
Common Stock, shares issued			219,500,000
Default Penalty to be recognized			$ 34,156
Convertible Prom Note #43
Date of Agreement	Apr. 4, 2017		Apr. 4, 2017
Convertible Note	$ 71,457		$ 71,457
Interest Rate	8.00%		8.00%
Due Date	Jan. 8, 2018		Jan. 8, 2018
Interest Accrued			$ 2,803
Convertible Prom Note #44
Date of Agreement	Apr. 18, 2017		Apr. 18, 2017
Convertible Note	$ 115,000		$ 115,000
Interest Rate	10.00%		10.00%
Due Date	Jan. 30, 2018		Jan. 30, 2018
Interest Accrued			$ 3,547
Original Issue Discount	$ 11,500		11,500
Original Issue Discount, unamortized			$ 3,889

Derivative Liabilities (Details

Derivative Liabilities (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Mar. 31, 2017	Mar. 31, 2016
Notes to Financial Statements
Change in value of derivative liability	$ (2,465,455)	$ (51,683)	$ (1,068,465)	$ (168,454)	$ 1,112,538	$ (563,432)
Derivative expense			(249,457)		(608,949)	$ (497,213)
Debt Discounts, Conversion Features	681,011		681,011		563,858
Debt Discount, Unamortized	174,572		174,572		356,819
Derivative liabilities	1,912,905		1,912,905		2,607,959
Derivative liabilities

Equity Transactions - Schedule

Equity Transactions - Schedule of Value of Warrants (Details) - USD ($)	6 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Mar. 31, 2017	Mar. 31, 2016
Fair value allocation of proceeds			$ 45,466
Warrant #10
Date	Mar. 30, 2017		Mar. 30, 2017
Warrants	$ 9,200,000		$ 9,200,000
Stock price on grant date	$ 0.002		$ 0.002
Exercise price	$ 0.002		$ 0.002
Expected life	5 years		5 years
Volatility	120.00%		120.00%
Risk-free rate	1.96%		1.96%
Calculated value	$ 15,278		$ 15,278
Fair value allocation of proceeds	$ 45,466		$ 45,466
Warrant #8
Date			Jun. 9, 2015
Warrants			$ 45,000
Stock price on grant date			$ 0.40
Exercise price			$ 0.40
Expected life			5 years
Volatility			98.00%
Risk-free rate			1.74%
Calculated value			$ 13,259
Fair value allocation of proceeds			$ 13,259
Warrant #9
Date			Dec. 15, 2015
Warrants			$ 200,000
Stock price on grant date			$ 0.20
Exercise price			$ 0.20
Expected life			5 years
Volatility			98.00%
Risk-free rate			1.71%
Calculated value			$ 29,612
Fair value allocation of proceeds			$ 29,612

Equity Transactions - Schedul42

Equity Transactions - Schedule of Warrant Activity (Details) - $ / shares	6 Months Ended	12 Months Ended
	Sep. 30, 2017	Mar. 31, 2017	Mar. 31, 2016
Accounting Policies [Abstract]
Beginning Balance, Issued Warrants	9,446,533	246,533
Beginning Balance, Average Exercise Price	$ 0.102	$ 3.84
Issued, Warrants
Issued, Average Exercise Price
Exercised, Warrants
Exercised, Average Exercise Price
Expired Warrants
Expired Average Exercise Price
Ending Balance, Issued Warrants	9,446,533	9,446,533	246,533
Ending Balance, Average Exercise Price	$ 0.102	$ 0.102	$ 3.84

Equity Transactions - Schedul43

Equity Transactions - Schedule of Value of Options (Details) - USD ($)	6 Months Ended	12 Months Ended
	Sep. 30, 2017	Mar. 31, 2017
Stock Option 7
Date of Issuance	Apr. 6, 2015	Apr. 6, 2015
Options	102,000	102,000
Stock price on grant date	$ 1.60	$ 1.60
Exercise price	1.60	1.60
Exercise price, modified	$ 0.20	$ 0.20
Expected life	5 years	5 years
Volatility	99.00%	99.00%
Risk-free rate	1.31%	1.31%
Calculated value	$ 120,778	$ 120,778
Modified value	$ 151,221	$ 151,221
Stock Option 8
Date of Issuance	Jun. 9, 2015	Jun. 9, 2015
Options	50,000	50,000
Stock price on grant date	$ 0.40	$ 0.40
Exercise price	0.40	0.40
Exercise price, modified	$ 0.20	$ 0.20
Expected life	5 years	5 years
Volatility	99.00%	99.00%
Risk-free rate	1.74%	1.74%
Calculated value	$ 14,838	$ 14,838
Modified value	$ 16,347	$ 16,347
Stock Option 9
Date of Issuance	Dec. 15, 2015	Dec. 15, 2015
Options	43,000	43,000
Stock price on grant date	$ 0.20	$ 0.20
Exercise price	0.20	0.20
Exercise price, modified	$ 0.20	$ 0.20
Expected life	5 years	5 years
Volatility	84.00%	84.00%
Risk-free rate	1.70%	1.70%
Calculated value	$ 5,736	$ 5,736
Modified value	$ 5,736	$ 5,736
Stock Option 10
Date of Issuance	Mar. 30, 2017	Mar. 30, 2017
Options	29,000,000	29,000,000
Stock price on grant date	$ 0.002	$ 0.002
Exercise price	$ 0.002	$ 0.002
Expected life	5 years	5 years
Volatility	120.00%	120.00%
Risk-free rate	1.93%	1.93%
Calculated value	$ 48,017	$ 48,017
Modified value	$ 48,017	$ 48,017

Equity Transactions - Schedul44

Equity Transactions - Schedule of Option Activity (Details) - shares	6 Months Ended	12 Months Ended
	Sep. 30, 2017	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Accounting Policies [Abstract]
Beginning Balance, number of shares	29,228,627	228,627
Beginning Balance, weighted average exercise price	0.004	0.20
Options granted, number of shares		29,000,000	195,000	9,875	23,752
Options granted, weighted average exercise price
Options exercised, number of shares
Options exercised, weighted average exercise price
Options expired, number of shares
Options expired, weighted average exercise price
Ending Balance, number of shares	29,228,627	29,228,627	228,627
Ending Balance, weighted average exercise price	0.004	0.004	0.20

Equity Transactions (Details Na

Equity Transactions (Details Narrative)

3 Months Ended

6 Months Ended

12 Months Ended

Sep. 30, 2017USD ($)$ / sharesshares

Jun. 30, 2017USD ($)shares

Sep. 30, 2016USD ($)

Sep. 30, 2017USD ($)$ / sharesshares

Sep. 30, 2016USD ($)

Mar. 31, 2017USD ($)$ / sharesshares

Mar. 31, 2016USD ($)$ / sharesshares

Mar. 31, 2015shares

Mar. 31, 2014shares

Mar. 31, 2013$ / sharesshares

May 09, 2017$ / sharesshares

Sep. 06, 2013$ / sharesshares

Sep. 05, 2013$ / sharesshares

Jul. 18, 2013shares

Common Stock, Shares Authorized | shares

2,000,000,000

2,000,000,000

2,000,000,000

2,000,000,000

375,030,000

2,000,000,000

375,030,000

900,000

Common Stock, Par Value | $ / shares

$ .001

$ .001

$ 0.001

$ 0.001

$ 0.001

$ 0.001

$ 0.001

$ 0.001

Preferred Stock, Shares Authorized | shares

10,000,000

10,000,000

10,000,000

Preferred Stock, Par Value | $ / shares

$ .001

$ .001

$ .001

Series A Preferred Stock, Designated | shares

6,000,000

Common Stock, Issued | shares

880,678,573

880,678,573

101,446,215

Preferred Stock, Issued | shares

6,000,000

6,000,000

6,000,000

Stock split ratio

0.05

0.05

0.05

0.01

4.1671

Options granted, number of shares | shares

29,000,000

195,000

9,875

23,752

Shares issued for services, value

$ 48,016

$ 48,016

Debt Instrument, Converted Amount

$ 277,208

$ 70,478

389,100

602,374

Stock-based compensation

48,016

$ 240,999

Common Stock Issued, Convertible Debt, Shares | shares

779,232,358

Adjustment to APIC

$ 502,027

Common stock to be issued

$ 100,000

100,000

2013 Stock Option Plan Amendment

Stock-based compensation

$ 50,448

2013 Stock Option Plan Amdt #2

Date of Agreement

Apr. 6, 2015

Options granted, number of shares | shares

135,627

Exercise price | $ / shares

$ 1.60

Stock-based compensation

$ 9,316

2013 Stock Option Plan Amdt #3

Date of Agreement

Aug. 4, 2015

Options granted, number of shares | shares

185,627

Exercise price | $ / shares

$ 0.40

Stock-based compensation

$ 47,463

Debt Conversion #65

Date of Issuance

Jan. 4, 2016

Common Stock, shares issued | shares

161,161

Common Stock, price per share | $ / shares

$ .12000

Debt Instrument, Converted Amount

$ 19,339

Debt Conversion #89

Date of Issuance

Apr. 1, 2016

Common Stock, shares issued | shares

488,316

Common Stock, price per share | $ / shares

$ .00450

Debt Instrument, Converted Amount

$ 2,197

Debt Conversion #90

Date of Issuance

Apr. 4, 2016

Common Stock, shares issued | shares

862,500

Common Stock, price per share | $ / shares

$ .00562

Debt Instrument, Converted Amount

$ 4,847

Debt Conversion #91

Date of Issuance

Apr. 7, 2016

Common Stock, shares issued | shares

486,111

Common Stock, price per share | $ / shares

$ .00360

Debt Instrument, Converted Amount

$ 1,750

Debt Conversion #92

Date of Issuance

Apr. 14, 2016

Common Stock, shares issued | shares

962,500

Common Stock, price per share | $ / shares

$ .00432

Debt Instrument, Converted Amount

$ 4,158

Debt Conversion #93

Date of Issuance

Apr. 15, 2016

Common Stock, shares issued | shares

488,311

Common Stock, price per share | $ / shares

$ .00270

Debt Instrument, Converted Amount

$ 1,318

Debt Conversion #94

Date of Issuance

Apr. 26, 2016

Common Stock, shares issued | shares

631,489

Common Stock, price per share | $ / shares

$ .00270

Debt Instrument, Converted Amount

$ 1,705

Debt Conversion #95

Date of Issuance

May 4, 2016

Common Stock, shares issued | shares

485,901

Common Stock, price per share | $ / shares

$ .00426

Debt Instrument, Converted Amount

$ 2,067

Debt Conversion #96

Date of Issuance

May 31, 2016

Common Stock, shares issued | shares

230,003

Common Stock, price per share | $ / shares

$ .00360

Debt Instrument, Converted Amount

$ 828

Debt Conversion #97

Date of Issuance

Jun. 2, 2016

Common Stock, shares issued | shares

1,500,000

Common Stock, price per share | $ / shares

$ .00608

Debt Instrument, Converted Amount

$ 9,120

Debt Conversion #98

Date of Issuance

Jun. 2, 2016

Common Stock, shares issued | shares

1,467,017

Common Stock, price per share | $ / shares

$ .00300

Debt Instrument, Converted Amount

$ 4,401

Debt Conversion #99

Date of Issuance

Jun. 14, 2016

Common Stock, shares issued | shares

1,461,795

Common Stock, price per share | $ / shares

$ .00400

Debt Instrument, Converted Amount

$ 5,847

Debt Conversion #100

Date of Issuance

Jun. 17, 2016

Common Stock, shares issued | shares

1,422,808

Common Stock, price per share | $ / shares

$ .00400

Debt Instrument, Converted Amount

$ 5,691

Debt Conversion #101

Date of Issuance

Jun. 29, 2017

Common Stock, shares issued | shares

1,063,518

Common Stock, price per share | $ / shares

$ .00618

Debt Instrument, Converted Amount

$ 6,580

Debt Conversion #102

Date of Issuance

Aug. 23, 2016

Common Stock, shares issued | shares

1,106,487

Common Stock, price per share | $ / shares

$ .00232

Debt Instrument, Converted Amount

$ 2,567

Debt Conversion #103

Date of Issuance

Aug. 29, 2016

Common Stock, shares issued | shares

1,107,806

Common Stock, price per share | $ / shares

$ .00232

Debt Instrument, Converted Amount

$ 2,570

Debt Conversion #104

Date of Issuance

Sep. 6, 2016

Common Stock, shares issued | shares

1,097,634

Common Stock, price per share | $ / shares

$ .00232

Debt Instrument, Converted Amount

$ 2,547

Debt Conversion #105

Date of Issuance

Sep. 20, 2016

Common Stock, shares issued | shares

1,263,383

Common Stock, price per share | $ / shares

$ .00194

Debt Instrument, Converted Amount

$ 2,443

Debt Conversion #106

Date of Issuance

Sep. 26, 2016

Common Stock, shares issued | shares

1,269,672

Common Stock, price per share | $ / shares

$ .00232

Debt Instrument, Converted Amount

$ 2,946

Debt Conversion #107

Date of Issuance

Sep. 28, 2016

Common Stock, shares issued | shares

1,270,172

Common Stock, price per share | $ / shares

$ .00232

Debt Instrument, Converted Amount

$ 2,947

Debt Conversion #108

Date of Issuance

Sep. 30, 2016

Common Stock, shares issued | shares

2,553,336

Common Stock, price per share | $ / shares

$ .00154

Debt Instrument, Converted Amount

$ 3,949

Debt Conversion #109

Date of Issuance

Oct. 7, 2016

Common Stock, shares issued | shares

2,914,578

Common Stock, price per share | $ / shares

$ .00116

Debt Instrument, Converted Amount

$ 3,381

Debt Conversion #110

Date of Issuance

Oct. 14, 2016

Common Stock, shares issued | shares

2,913,784

Common Stock, price per share | $ / shares

$ .00116

Debt Instrument, Converted Amount

$ 3,380

Debt Conversion #111

Date of Issuance

Oct. 21, 2016

Common Stock, shares issued | shares

2,917,784

Common Stock, price per share | $ / shares

$ .00116

Debt Instrument, Converted Amount

$ 3,385

Debt Conversion #112

Date of Issuance

Oct. 26, 2016

Common Stock, shares issued | shares

2,915,828

Common Stock, price per share | $ / shares

$ .00116

Debt Instrument, Converted Amount

$ 3,382

Debt Conversion #113

Date of Issuance

Oct. 31, 2016

Common Stock, shares issued | shares

4,341,853

Common Stock, price per share | $ / shares

$ .00116

Debt Instrument, Converted Amount

$ 5,037

Debt Conversion #114

Date of Issuance

Nov. 7, 2016

Common Stock, shares issued | shares

4,323,647

Common Stock, price per share | $ / shares

$ .00116

Debt Instrument, Converted Amount

$ 5,015

Debt Conversion #115

Date of Issuance

Nov. 22, 2016

Common Stock, shares issued | shares

4,753,009

Common Stock, price per share | $ / shares

$ .00116

Debt Instrument, Converted Amount

$ 5,513

Debt Conversion #116

Date of Issuance

Nov. 29, 2016

Common Stock, shares issued | shares

4,754,647

Common Stock, price per share | $ / shares

$ .00116

Debt Instrument, Converted Amount

$ 5,515

Debt Conversion #117

Date of Issuance

Dec. 6, 2016

Common Stock, shares issued | shares

3,497,966

Common Stock, price per share | $ / shares

$ .00116

Debt Instrument, Converted Amount

$ 4,058

Debt Conversion #118

Date of Issuance

Jan. 10, 2017

Common Stock, shares issued | shares

6,301,150

Common Stock, price per share | $ / shares

$ 0.00100

Debt Instrument, Converted Amount

$ 6,301

Debt Conversion #119

Date of Issuance

Feb. 22, 2017

Common Stock, shares issued | shares

3,575,000

Common Stock, price per share | $ / shares

$ 0.00120

Debt Instrument, Converted Amount

$ 4,290

Debt Conversion #120

Date of Issuance

Mar. 13, 2017

Common Stock, shares issued | shares

3,400,000

Common Stock, price per share | $ / shares

$ 0.00120

Debt Instrument, Converted Amount

$ 4,080

Debt Conversion #121

Date of Issuance

Mar. 21, 2017

Common Stock, shares issued | shares

4,100,000

Common Stock, price per share | $ / shares

$ 0.00120

Debt Instrument, Converted Amount

$ 4,920

Debt Conversion #122

Date of Issuance

Mar. 22, 2017

Common Stock, shares issued | shares

4,300,000

Common Stock, price per share | $ / shares

$ 0.00120

Debt Instrument, Converted Amount

$ 5,160

Debt Conversion #123

Date of Issuance

Mar. 24, 2017

Common Stock, shares issued | shares

4,550,000

Common Stock, price per share | $ / shares

$ 0.00120

Debt Instrument, Converted Amount

$ 5,460

Debt Conversion #124

Date of Issuance

Mar. 30, 2017

Common Stock, shares issued | shares

4,800,000

Common Stock, price per share | $ / shares

$ 0.00118

Debt Instrument, Converted Amount

$ 5,645

Debt Conversion #125

Date of Issuance

Mar. 31, 2017

Common Stock, shares issued | shares

5,050,000

Common Stock, price per share | $ / shares

$ 0.00118

Debt Instrument, Converted Amount

$ 5,939

Debt Conversion #126

Date of Issuance

Apr. 5, 2017

Apr. 5, 2017

Common Stock, shares issued | shares

5,300,000

5,300,000

Common Stock, price per share | $ / shares

$ 0.00118

Debt Instrument, Converted Amount

$ 6,004

$ 6,233

Debt Conversion #127

Date of Issuance

Apr. 10, 2017

Apr. 10, 2017

Common Stock, shares issued | shares

5,600,000

5,600,000

Common Stock, price per share | $ / shares

$ 0.00118

Debt Instrument, Converted Amount

$ 6,363

$ 6,586

Debt Conversion #128

Date of Issuance

Apr. 11, 2017

Apr. 11, 2017

Common Stock, shares issued | shares

5,850,000

5,850,000

Common Stock, price per share | $ / shares

$ 0.00118

Debt Instrument, Converted Amount

$ 6,004

$ 6,880

Debt Conversion #129

Date of Issuance

Apr. 18, 2017

Apr. 18, 2017

Common Stock, shares issued | shares

6,200,000

6,200,000

Common Stock, price per share | $ / shares

$ 0.00118

Debt Instrument, Converted Amount

$ 7,000

$ 7,291

Debt Conversion #130

Date of Issuance

Apr. 20, 2017

Apr. 20, 2017

Common Stock, shares issued | shares

6,500,000

6,500,000

Common Stock, price per share | $ / shares

$ 0.00118

Debt Instrument, Converted Amount

$ 7,564

$ 7,644

Debt Conversion #131

Date of Issuance

Apr. 21, 2017

Apr. 21, 2017

Common Stock, shares issued | shares

14,000,000

14,000,000

Common Stock, price per share | $ / shares

$ 0.00118

Debt Instrument, Converted Amount

$ 16,426

$ 16,464

Debt Conversion #132

Date of Issuance

Apr. 25, 2017

Apr. 25, 2017

Common Stock, shares issued | shares

14,700,000

14,700,000

Common Stock, price per share | $ / shares

$ 0.00118

Debt Instrument, Converted Amount

$ 17,148

$ 17,287

Debt Conversion #133

Date of Issuance

Apr. 26, 2017

Apr. 26, 2017

Common Stock, shares issued | shares

26,600,000

26,600,000

Common Stock, price per share | $ / shares

$ 0.001

Debt Instrument, Converted Amount

$ 25,000

$ 26,600

Debt Conversion #134

Date of Issuance

May 1, 2017

May 1, 2017

Common Stock, shares issued | shares

14,500,000

14,500,000

Common Stock, price per share | $ / shares

$ 0.00060

Debt Instrument, Converted Amount

$ 8,514

$ 8,700

Debt Conversion #135

Date of Issuance

Jun. 13, 2017

Jun. 13, 2017

Common Stock, shares issued | shares

10,000,000

10,000,000

Common Stock, price per share | $ / shares

$ 0.00012

Debt Instrument, Converted Amount

$ 1,200

Debt Conversion #136

Date of Issuance

Jun. 16, 2017

Jun. 16, 2017

Common Stock, shares issued | shares

11,000,000

11,000,000

Common Stock, price per share | $ / shares

$ 0.00010

Debt Instrument, Converted Amount

$ 1,158

$ 1,930

Debt Conversion #137

Date of Issuance

Jun. 16, 2017

Jun. 16, 2017

Common Stock, shares issued | shares

19,299,400

19,299,400

Common Stock, price per share | $ / shares

$ 0.00012

Debt Instrument, Converted Amount

$ 1,795

$ 1,300

Debt Conversion #138

Date of Issuance

Jun. 20, 2017

Jun. 20, 2017

Common Stock, shares issued | shares

11,600,000

11,600,000

Common Stock, price per share | $ / shares

$ 0.00012

Debt Instrument, Converted Amount

$ 1,276

$ 1,382

Debt Conversion #139

Date of Issuance

Jun. 21, 2017

Jun. 21, 2017

Common Stock, shares issued | shares

23,139,900

23,139,900

Common Stock, price per share | $ / shares

$ 0.00010

Debt Instrument, Converted Amount

$ 2,150

$ 2,314

Debt Conversion #140

Date of Issuance

Jun. 22, 2017

Jun. 22, 2017

Common Stock, shares issued | shares

12,250,000

12,250,000

Common Stock, price per share | $ / shares

$ 0.00012

Debt Instrument, Converted Amount

$ 1,413

$ 1,590

Debt Conversion #141

Date of Issuance

Jun. 22, 2017

Jun. 22, 2017

Common Stock, shares issued | shares

13,250,000

13,250,000

Common Stock, price per share | $ / shares

$ 0.00012

Debt Instrument, Converted Amount

$ 1,590

$ 1,470

Debt Conversion #142

Date of Issuance

Jun. 26, 2017

Jun. 26, 2017

Common Stock, shares issued | shares

15,000,000

15,000,000

Common Stock, price per share | $ / shares

$ 0.00012

Debt Instrument, Converted Amount

$ 1,688

$ 1,800

Debt Conversion #143

Date of Issuance

Jun. 29, 2017

Jun. 29, 2017

Common Stock, shares issued | shares

16,500,000

16,500,000

Common Stock, price per share | $ / shares

$ 0.00012

Debt Instrument, Converted Amount

$ 1,897

$ 1,980

Debt Conversion #144

Date of Issuance

Jul. 3, 2017

Jul. 3, 2017

Common Stock, shares issued | shares

17,400,000

17,400,000

Common Stock, price per share | $ / shares

$ 0.00012

Debt Instrument, Converted Amount

$ 1,979

$ 2,088

Debt Conversion #145

Date of Issuance

Jul. 12, 2017

Jul. 12, 2017

Common Stock, shares issued | shares

17,400,000

17,400,000

Common Stock, price per share | $ / shares

$ 0.00012

Debt Instrument, Converted Amount

$ 2,088

Debt Conversion #146

Date of Issuance

Jul. 13, 2017

Jul. 13, 2017

Common Stock, shares issued | shares

13,800,000

13,800,000

Common Stock, price per share | $ / shares

$ 0.00018

Debt Instrument, Converted Amount

$ 1,344

$ 2,484

Debt Conversion #147

Date of Issuance

Jul. 14, 2017

Jul. 14, 2017

Common Stock, shares issued | shares

19,000,000

19,000,000

Common Stock, price per share | $ / shares

$ 0.00018

Debt Instrument, Converted Amount

$ 3,358

$ 3,374

Debt Conversion #148

Date of Issuance

Jul. 3, 2017

Jul. 3, 2017

Common Stock, shares issued | shares

19,000,000

19,000,000

Common Stock, price per share | $ / shares

$ 0.00018

Debt Instrument, Converted Amount

$ 3,314

$ 3,374

Debt Conversion #149

Date of Issuance

Jul. 20, 2017

Jul. 20, 2017

Common Stock, shares issued | shares

19,900,000

19,900,000

Common Stock, price per share | $ / shares

$ 0.00018

Debt Instrument, Converted Amount

$ 3,554

$ 3,582

Debt Conversion #150

Date of Issuance

Jul. 24, 2017

Jul. 24, 2017

Common Stock, shares issued | shares

20,900,000

20,900,000

Common Stock, price per share | $ / shares

$ 0.0003

Debt Instrument, Converted Amount

$ 6,217

$ 6,270

Debt Conversion #151

Date of Issuance

Jul. 25, 2017

Jul. 25, 2017

Common Stock, shares issued | shares

22,900,000

22,900,000

Common Stock, price per share | $ / shares

$ 0.0003

Debt Instrument, Converted Amount

$ 6,022

$ 6,870

Debt Conversion #152

Date of Issuance

Jul. 28, 2017

Jul. 28, 2017

Common Stock, shares issued | shares

24,000,000

24,000,000

Common Stock, price per share | $ / shares

$ 0.0003

Debt Instrument, Converted Amount

$ 7,089

$ 7,200

Debt Conversion #153

Date of Issuance

Aug. 2, 2017

Aug. 2, 2017

Common Stock, shares issued | shares

24,000,000

24,000,000

Common Stock, price per share | $ / shares

$ 0.0003

Debt Instrument, Converted Amount

$ 7,035

$ 7,200

Debt Conversion #154

Date of Issuance

Aug. 4, 2017

Aug. 4, 2017

Common Stock, shares issued | shares

25,000,000

25,000,000

Common Stock, price per share | $ / shares

$ 0.00036

Debt Instrument, Converted Amount

$ 8,942

$ 9,000

Debt Conversion #155

Date of Issuance

Aug. 8, 2017

Aug. 8, 2017

Common Stock, shares issued | shares

26,475,000

26,475,000

Common Stock, price per share | $ / shares

$ 0.00042

Debt Instrument, Converted Amount

$ 11,022

$ 11,119

Debt Conversion #156

Date of Issuance

Aug. 11, 2017

Aug. 11, 2017

Common Stock, shares issued | shares

29,000,000

29,000,000

Common Stock, price per share | $ / shares

$ 0.00048

Debt Instrument, Converted Amount

$ 13,920

$ 13,920

Debt Conversion #157

Date of Issuance

Aug. 16, 2017

Aug. 16, 2017

Common Stock, shares issued | shares

30,500,000

30,500,000

Common Stock, price per share | $ / shares

$ 0.00042

Debt Instrument, Converted Amount

$ 12,810

$ 12,810

Debt Conversion #158

Date of Issuance

Aug. 22, 2017

Common Stock, shares issued | shares

19,168,058

Common Stock, price per share | $ / shares

$ 0.00035

Debt Instrument, Converted Amount

$ 6,709

Debt Conversion #159

Date of Issuance

Aug. 25, 2017

Common Stock, shares issued | shares

32,000,000

Common Stock, price per share | $ / shares

$ 0.00035

Debt Instrument, Converted Amount

$ 11,200

Debt Conversion #160

Date of Issuance

Aug. 31, 2017

Common Stock, shares issued | shares

32,000,000

Common Stock, price per share | $ / shares

$ 0.0003

Debt Instrument, Converted Amount

$ 9,600

Debt Conversion #161

Date of Issuance

Sep. 7, 2017

Common Stock, shares issued | shares

36,000,000

Common Stock, price per share | $ / shares

$ 0.00028

Debt Instrument, Converted Amount

$ 9,900

Debt Conversion #162

Date of Issuance

Sep. 15, 2017

Common Stock, shares issued | shares

37,900,000

Common Stock, price per share | $ / shares

$ 0.00025

Debt Instrument, Converted Amount

$ 9,437

Debt Conversion #163

Date of Issuance

Sep. 22, 2017

Common Stock, shares issued | shares

39,800,000

Common Stock, price per share | $ / shares

$ 0.00025

Debt Instrument, Converted Amount

$ 9,910

Debt Conversion #164

Date of Issuance

Sep. 28, 2017

Common Stock, shares issued | shares

41,800,000

Common Stock, price per share | $ / shares

$ 0.00025

Debt Instrument, Converted Amount

$ 10,408

Stock Sub Agmt

Date of Agreement

Oct. 16, 2017

Warrants

$ 333,333,333

Exercise price | $ / shares

$ 0.0003

Expected life

5 years

Common Stock, Subscribed but Unissued | shares

333,333,333

333,333,333

Common stock to be issued

$ 100,000

$ 100,000

Warrant #10

Exercise Date

Mar. 30, 2017

Mar. 30, 2017

Warrants

$ 9,200,000

$ 9,200,000

Stock price on grant date | $ / shares

$ 0.002

$ 0.002

Exercise price | $ / shares

$ 0.002

$ 0.002

Expected life

5 years

5 years

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	6 Months Ended	12 Months Ended
	Sep. 30, 2017	Mar. 31, 2017
Monthly Rent	$ 2,800	$ 2,800
Contract
Date of Agreement	Jul. 8, 2016	Jul. 8, 2016
Contract Duration	27 months	27 months
Contract Committment Value	$ 193,255	$ 193,255
CannCodex
Date of Agreement	Apr. 1, 2017
Shares issued for services	78,000,000
Loan payable	$ 15,300

Subsequent Event (Details Narra

Subsequent Event (Details Narrative)	3 Months Ended			6 Months Ended		9 Months Ended	12 Months Ended
	Sep. 30, 2017USD ($)$ / sharesshares	Jun. 30, 2017	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)$ / sharesshares	Sep. 30, 2016USD ($)	Dec. 31, 2017USD ($)$ / sharesshares	Mar. 31, 2017USD ($)$ / sharesshares	Mar. 31, 2016USD ($)$ / sharesshares	Mar. 31, 2013$ / sharesshares	May 09, 2017$ / sharesshares	Sep. 06, 2013$ / sharesshares	Sep. 05, 2013$ / sharesshares
Debt Instrument, Converted Amount				$ 277,208	$ 70,478		$ 389,100	$ 602,374
Common Stock, Par Value | $ / shares	$ .001			$ .001			$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Common Stock, Shares Authorized | shares	2,000,000,000			2,000,000,000			2,000,000,000	2,000,000,000	375,030,000	2,000,000,000	375,030,000	900,000
Stock split ratio		0.05		0.05			0.05	0.01	4.1671
Accrued expenses	$ 1,188,520			$ 1,188,520			$ 937,783	$ 530,150
Consulting expenses	$ 95,375		$ 5,850	$ 100,000	$ 16,075		$ 45,554	$ 16,000
Consulting Agmt #2
Date of Agreement						Nov. 13, 2017
Consulting expenses						$ 7,000
Debt Conversion #165
Date of Issuance						Oct. 3, 2017
Debt Instrument, Converted Amount						$ 10,931
Common Stock, shares issued | shares						43,900,000
Common Stock, price per share | $ / shares						$ 0.00025
Debt Conversion #166
Date of Issuance						Oct. 5, 2017
Debt Instrument, Converted Amount						$ 7,582
Common Stock, shares issued | shares						30,448,193
Common Stock, price per share | $ / shares						$ 0.00025
Convertible Prom Note #45
Convertible Note						$ 34,500
Interest Rate						10.00%
Due Date						Aug. 3, 2018
Date of Issuance						Nov. 3, 2017
Original Issue Discount						$ 3,450

Subsequent Event (Details Nar48

Subsequent Event (Details Narrative) 12M	3 Months Ended	6 Months Ended		12 Months Ended
	Jun. 30, 2017USD ($)shares	Sep. 30, 2017USD ($)$ / sharesshares	Sep. 30, 2016USD ($)	Mar. 31, 2017USD ($)$ / sharesshares	Mar. 31, 2016USD ($)$ / sharesshares	Mar. 31, 2013$ / sharesshares	May 15, 2017USD ($)	May 09, 2017$ / sharesshares	Sep. 06, 2013$ / sharesshares	Sep. 05, 2013$ / sharesshares
Debt Instrument, Converted Amount		$ 277,208	$ 70,478	$ 389,100	$ 602,374
Debt Instrument, Interest Accrued, Converted Amount				$ 11,010
Common Stock, Par Value | $ / shares		$ .001		$ 0.001	$ 0.001	$ 0.001		$ 0.001	$ 0.001	$ 0.001
Common Stock, Shares Authorized | shares		2,000,000,000		2,000,000,000	2,000,000,000	375,030,000		2,000,000,000	375,030,000	900,000
Stock split ratio	0.05	0.05		0.05	0.01	4.1671
Accrued expenses		$ 1,188,520		$ 937,783	$ 530,150
Related Party Loans
Interest Rate	0.00%
Due Date	May 15, 2018
Accrued expenses				$ 14,450	$ 22,200		$ 5,300
Consulting Agmt
Date of Agreement	Jul. 7, 2017
Term of Agreement	2 years
Annual Compensation	$ 180,000
Collaboration Agmt
Date of Agreement	Jul. 11, 2017	Jul. 11, 2017
Account Receivable	$ 100,000
Common Stock, Receivable | shares	15,000,000
Convertible Prom Note #43
Date of Agreement	Apr. 4, 2017	Apr. 4, 2017
Convertible Note	$ 71,457	$ 71,457
Interest Rate	8.00%	8.00%
Due Date	Jan. 8, 2018	Jan. 8, 2018
Convertible Prom Note #44
Date of Agreement	Apr. 18, 2017	Apr. 18, 2017
Convertible Note	$ 115,000	$ 115,000
Interest Rate	10.00%	10.00%
Due Date	Jan. 30, 2018	Jan. 30, 2018
Original Issue Discount	$ 11,500	$ 11,500
Debt Conversion #126
Date of Issuance	Apr. 5, 2017	Apr. 5, 2017
Debt Instrument, Converted Amount	$ 6,004	$ 6,233
Debt Instrument, Interest Accrued, Converted Amount	$ 229
Common Stock, shares issued | shares	5,300,000	5,300,000
Debt Conversion #127
Date of Issuance	Apr. 10, 2017	Apr. 10, 2017
Debt Instrument, Converted Amount	$ 6,363	$ 6,586
Debt Instrument, Interest Accrued, Converted Amount	$ 222
Common Stock, shares issued | shares	5,600,000	5,600,000
Debt Conversion #128
Date of Issuance	Apr. 11, 2017	Apr. 11, 2017
Debt Instrument, Converted Amount	$ 6,004	$ 6,880
Debt Instrument, Interest Accrued, Converted Amount	$ 43
Common Stock, shares issued | shares	5,850,000	5,850,000
Debt Conversion #129
Date of Issuance	Apr. 18, 2017	Apr. 18, 2017
Debt Instrument, Converted Amount	$ 7,000	$ 7,291
Debt Instrument, Interest Accrued, Converted Amount	$ 291
Common Stock, shares issued | shares	6,200,000	6,200,000
Debt Conversion #130
Date of Issuance	Apr. 20, 2017	Apr. 20, 2017
Debt Instrument, Converted Amount	$ 7,564	$ 7,644
Debt Instrument, Interest Accrued, Converted Amount	$ 80
Common Stock, shares issued | shares	6,500,000	6,500,000
Debt Conversion #131
Date of Issuance	Apr. 21, 2017	Apr. 21, 2017
Debt Instrument, Converted Amount	$ 16,426	$ 16,464
Debt Instrument, Interest Accrued, Converted Amount	$ 38
Common Stock, shares issued | shares	14,000,000	14,000,000
Debt Conversion #132
Date of Issuance	Apr. 25, 2017	Apr. 25, 2017
Debt Instrument, Converted Amount	$ 17,148	$ 17,287
Debt Instrument, Interest Accrued, Converted Amount	$ 139
Common Stock, shares issued | shares	14,700,000	14,700,000
Debt Conversion #133
Date of Issuance	Apr. 26, 2017	Apr. 26, 2017
Debt Instrument, Converted Amount	$ 25,000	$ 26,600
Debt Instrument, Interest Accrued, Converted Amount	$ 1,600
Common Stock, shares issued | shares	26,600,000	26,600,000
Debt Conversion #134
Date of Issuance	May 1, 2017	May 1, 2017
Debt Instrument, Converted Amount	$ 8,514	$ 8,700
Debt Instrument, Interest Accrued, Converted Amount	$ 186
Common Stock, shares issued | shares	14,500,000	14,500,000
Debt Conversion #135
Date of Issuance	Jun. 13, 2017	Jun. 13, 2017
Debt Instrument, Converted Amount		$ 1,200
Debt Instrument, Interest Accrued, Converted Amount	$ 1,200
Common Stock, shares issued | shares	10,000,000	10,000,000
Debt Conversion #136
Date of Issuance	Jun. 16, 2017	Jun. 16, 2017
Debt Instrument, Converted Amount	$ 1,158	$ 1,930
Debt Instrument, Interest Accrued, Converted Amount	$ 142
Common Stock, shares issued | shares	11,000,000	11,000,000
Debt Conversion #137
Date of Issuance	Jun. 16, 2017	Jun. 16, 2017
Debt Instrument, Converted Amount	$ 1,795	$ 1,300
Debt Instrument, Interest Accrued, Converted Amount	$ 135
Common Stock, shares issued | shares	19,299,400	19,299,400
Debt Conversion #138
Date of Issuance	Jun. 20, 2017	Jun. 20, 2017
Debt Instrument, Converted Amount	$ 1,276	$ 1,382
Debt Instrument, Interest Accrued, Converted Amount	$ 116
Common Stock, shares issued | shares	11,600,000	11,600,000
Debt Conversion #139
Date of Issuance	Jun. 21, 2017	Jun. 21, 2017
Debt Instrument, Converted Amount	$ 2,150	$ 2,314
Debt Instrument, Interest Accrued, Converted Amount	$ 164
Common Stock, shares issued | shares	23,139,900	23,139,900
Debt Conversion #140
Date of Issuance	Jun. 22, 2017	Jun. 22, 2017
Debt Instrument, Converted Amount	$ 1,413	$ 1,590
Debt Instrument, Interest Accrued, Converted Amount	$ 57
Common Stock, shares issued | shares	12,250,000	12,250,000
Debt Conversion #141
Date of Issuance	Jun. 22, 2017	Jun. 22, 2017
Debt Instrument, Converted Amount	$ 1,590	$ 1,470
Common Stock, shares issued | shares	13,250,000	13,250,000
Debt Conversion #142
Date of Issuance	Jun. 26, 2017	Jun. 26, 2017
Debt Instrument, Converted Amount	$ 1,688	$ 1,800
Debt Instrument, Interest Accrued, Converted Amount	$ 112
Common Stock, shares issued | shares	15,000,000	15,000,000
Debt Conversion #143
Date of Issuance	Jun. 29, 2017	Jun. 29, 2017
Debt Instrument, Converted Amount	$ 1,897	$ 1,980
Debt Instrument, Interest Accrued, Converted Amount	$ 83
Common Stock, shares issued | shares	16,500,000	16,500,000
Debt Conversion #144
Date of Issuance	Jul. 3, 2017	Jul. 3, 2017
Debt Instrument, Converted Amount	$ 1,979	$ 2,088
Debt Instrument, Interest Accrued, Converted Amount	$ 109
Common Stock, shares issued | shares	17,400,000	17,400,000
Debt Conversion #145
Date of Issuance	Jul. 12, 2017	Jul. 12, 2017
Debt Instrument, Converted Amount		$ 2,088
Debt Instrument, Interest Accrued, Converted Amount	$ 2,088
Common Stock, shares issued | shares	17,400,000	17,400,000
Debt Conversion #146
Date of Issuance	Jul. 13, 2017	Jul. 13, 2017
Debt Instrument, Converted Amount	$ 1,344	$ 2,484
Debt Instrument, Interest Accrued, Converted Amount	$ 1,140
Common Stock, shares issued | shares	13,800,000	13,800,000
Debt Conversion #147
Date of Issuance	Jul. 14, 2017	Jul. 14, 2017
Debt Instrument, Converted Amount	$ 3,358	$ 3,374
Debt Instrument, Interest Accrued, Converted Amount	$ 16
Common Stock, shares issued | shares	19,000,000	19,000,000
Debt Conversion #148
Date of Issuance	Jul. 3, 2017	Jul. 3, 2017
Debt Instrument, Converted Amount	$ 3,314	$ 3,374
Debt Instrument, Interest Accrued, Converted Amount	$ 60
Common Stock, shares issued | shares	19,000,000	19,000,000
Debt Conversion #149
Date of Issuance	Jul. 20, 2017	Jul. 20, 2017
Debt Instrument, Converted Amount	$ 3,554	$ 3,582
Debt Instrument, Interest Accrued, Converted Amount	$ 28
Common Stock, shares issued | shares	19,900,000	19,900,000
Debt Conversion #150
Date of Issuance	Jul. 24, 2017	Jul. 24, 2017
Debt Instrument, Converted Amount	$ 6,217	$ 6,270
Debt Instrument, Interest Accrued, Converted Amount	$ 53
Common Stock, shares issued | shares	20,900,000	20,900,000
Debt Conversion #151
Date of Issuance	Jul. 25, 2017	Jul. 25, 2017
Debt Instrument, Converted Amount	$ 6,022	$ 6,870
Debt Instrument, Interest Accrued, Converted Amount	$ 848
Common Stock, shares issued | shares	22,900,000	22,900,000
Debt Conversion #152
Date of Issuance	Jul. 28, 2017	Jul. 28, 2017
Debt Instrument, Converted Amount	$ 7,089	$ 7,200
Debt Instrument, Interest Accrued, Converted Amount	$ 111
Common Stock, shares issued | shares	24,000,000	24,000,000
Debt Conversion #153
Date of Issuance	Aug. 2, 2017	Aug. 2, 2017
Debt Instrument, Converted Amount	$ 7,035	$ 7,200
Debt Instrument, Interest Accrued, Converted Amount	$ 165
Common Stock, shares issued | shares	24,000,000	24,000,000
Debt Conversion #154
Date of Issuance	Aug. 4, 2017	Aug. 4, 2017
Debt Instrument, Converted Amount	$ 8,942	$ 9,000
Debt Instrument, Interest Accrued, Converted Amount	$ 58
Common Stock, shares issued | shares	25,000,000	25,000,000
Debt Conversion #155
Date of Issuance	Aug. 8, 2017	Aug. 8, 2017
Debt Instrument, Converted Amount	$ 11,022	$ 11,119
Debt Instrument, Interest Accrued, Converted Amount	$ 97
Common Stock, shares issued | shares	26,475,000	26,475,000
Debt Conversion #156
Date of Issuance	Aug. 11, 2017	Aug. 11, 2017
Debt Instrument, Converted Amount	$ 13,920	$ 13,920
Common Stock, shares issued | shares	29,000,000	29,000,000
Debt Conversion #157
Date of Issuance	Aug. 16, 2017	Aug. 16, 2017
Debt Instrument, Converted Amount	$ 12,810	$ 12,810
Common Stock, shares issued | shares	30,500,000	30,500,000